0001493152-26-011924 | 10-K | XBRL Viewer

Print Document

Schedule of Accrued Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Payables and Accruals [Abstract]
Payroll and related expenses	$ 120	$ 400
Accrued payables	50	178
Other	252	408
Accrued liabilities	$ 422	$ 986

Cybersecurity Risk Management and Strategy Disclosure	12 Months Ended
Cybersecurity Risk Management and Strategy Disclosure	Dec. 31, 2025
Cybersecurity Risk Management, Strategy, and Governance [Abstract]
Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]	Risk Management and Strategy We maintain processes designed to assess, identify, and manage material risks from cybersecurity threats to our information technology systems and data. These processes are integrated into our broader risk management activities and are intended to protect the confidentiality, integrity, and availability of our systems and information. We rely on information technology systems to support our manufacturing operations, supply chain management, inventory and distribution activities, research and development, financial reporting, and corporate functions. To protect these systems, we implement a range of technical and administrative safeguards, including access controls, network monitoring tools, data backup procedures, incident response protocols, and employee cybersecurity awareness training. We periodically assess our systems for vulnerabilities and engage third-party service providers, as appropriate, to assist in evaluating and strengthening our cybersecurity posture. We also maintain processes to assess cybersecurity risks associated with certain third-party vendors and service providers that have access to our systems or data. These processes may include due diligence, contractual safeguards, and ongoing oversight, as appropriate based on the nature of the services provided. As of the date of this Annual Report, we have not identified any cybersecurity incidents that have materially affected, or are reasonably likely to materially affect, our business strategy, results of operations, or financial condition. However, cybersecurity threats are continually evolving, and there can be no assurance that our processes and controls will be sufficient to prevent all incidents. For additional information regarding cybersecurity risks, see Part I, Item 1A. “Risk Factors.”
Cybersecurity Risk Management Processes Integrated [Flag]	true
Cybersecurity Risk Management Processes Integrated [Text Block]	We maintain processes designed to assess, identify, and manage material risks from cybersecurity threats to our information technology systems and data. These processes are integrated into our broader risk management activities and are intended to protect the confidentiality, integrity, and availability of our systems and information.
Cybersecurity Risk Management Third Party Engaged [Flag]	true
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]	false
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]	As of the date of this Annual Report, we have not identified any cybersecurity incidents that have materially affected, or are reasonably likely to materially affect, our business strategy, results of operations, or financial condition.
Cybersecurity Risk Board of Directors Oversight [Text Block]	Governance Our Board of Directors has oversight responsibility for risk management, including risks arising from cybersecurity threats. The Board receives periodic updates from management regarding cybersecurity matters, including risk exposures, mitigation efforts, and significant developments, as appropriate. Management is responsible for the day-to-day management of cybersecurity risk. Members of senior management oversee the Company’s cybersecurity policies, procedures, and controls, coordinate efforts across relevant functional areas, and lead response efforts in the event of a cybersecurity incident. Management reports to the Board on cybersecurity risks and related matters on a periodic basis and would promptly inform the Board of any material cybersecurity incident.
Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]	Our Board of Directors has oversight responsibility for risk management, including risks arising from cybersecurity threats. The Board receives periodic updates from management regarding cybersecurity matters, including risk exposures, mitigation efforts, and significant developments, as appropriate.
Cybersecurity Risk Management Positions or Committees Responsible [Flag]	true
Cybersecurity Risk Management Positions or Committees Responsible [Text Block]	Management is responsible for the day-to-day management of cybersecurity risk. Members of senior management oversee the Company’s cybersecurity policies, procedures, and controls, coordinate efforts across relevant functional areas, and lead response efforts in the event of a cybersecurity incident.

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Dec. 31, 2025
Insider Trading Arrangements [Line Items]
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Accrued Liabilities (Details Narrative) - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Payables and Accruals [Abstract]
Other current liabilities	$ 1,697	$ 1

Fair Value Measurements

12 Months Ended

Dec. 31, 2025

Fair Value Disclosures [Abstract]

Fair Value Measurements

5. Fair Value Measurements

Financial Instruments Measured and Recorded at Fair Value on a Recurring Basis

The Company has issued certain warrants to purchase shares of common stock, which are considered mark-to-market liabilities and are re-measured to fair value at each reporting period in accordance with accounting guidance. Fair value is based on the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, under a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value as follows:

Level 1	-	quoted market prices for identical assets or liabilities in active markets.

Level 2	-	observable prices that are based on inputs not quoted on active markets but corroborated by market data.

Level 3	-	unobservable inputs reflecting management’s assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment.

The Company classifies assets and liabilities measured at fair value in their entirety based on the lowest level of input that is significant to their fair value measurement. No financial assets were measured on a recurring basis as of December 31, 2025 and 2024. The following tables set forth the financial liabilities measured at fair value on a recurring basis by level within the fair value hierarchy as of December 31, 2025 and 2024.

	Fair Value Measurements as of December 31, 2025 (in thousands)
Description	Level 1		Level 2		Level 3		Total
Derivative liabilities
Common stock warrants	$	-	$	-	$	827	$	827

	Fair Value Measurements as of December 31, 2024 (in thousands)
Description	Level 1		Level 2		Level 3		Total
Derivative liabilities
Common stock warrants	$	-	$	-	$	208	$	208

The Company did not have any transfers of assets and liabilities between Level 1 and Level 2 of the fair value measurement hierarchy during the years ended December 31, 2025 and 2024. The following table presents a reconciliation of the derivative liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the years ended December 31, 2025 and 2024 (in thousands):

	Common Stock Warrants
Balance as of December 31, 2023	$	304
Issuance of derivatives		3,366
Exercise of warrants		(1	)
Change in fair value		(3,475	)
Other		14
Balance as of December 31, 2024	$	208
Issuance of derivatives		495
Change in fair value		124
Balance as of December 31, 2025	$	827

Common Stock Warrants

The Company has issued certain warrants to purchase shares of common stock, which are considered derivative liabilities because they have registration rights which could require a cash settlement and are re-measured to fair value at each reporting period in accordance with accounting guidance. As of December 31, 2025, and 2024, the derivative liability was calculated using the Monte Carlo Simulation valuation.

The assumptions used in estimating the common stock warrant liability using the Monte Carlo simulation valuation model as of December 31, 2025 and 2024 were as follows:

	December 31, 2025			December 31, 2024
Weighted-average risk-free interest rate		3.42-3.65	%		4.12-4.35	%
Weighted-average expected life (in years)		0.11-4.48			0.10-4.09
Expected dividend yield		-	%		-	%
Weighted average expected volatility		115.0-175.0	%		140.0%-210.0	%

Other Financial Instruments

The Company’s recorded values of cash and cash equivalents, account and other receivables, accounts payable and accrued liabilities approximate their fair values based on their short-term nature. The recorded value of notes payable approximates the fair value as the interest rate approximates market interest rates.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 107
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-107

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 100
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-100

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2E
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 940
-SubTopic 820
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478119/940-820-50-1

+ Details

Organization and Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2025

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of Major Classes of Assets and Liabilities of TA & T at the Date of Sale

The following table summarizes the carrying amounts of the major classes of assets and liabilities of TA&T at the date of sale that were transferred to the Tethon (in thousands):

	February 19, 2025
Cash and cash equivalents	$	4
Inventories		8
Accounts receivable		91
Right of use asset		376
Property and equipment, net		248
Other assets		16
Total assets sold		743
Accounts payable		(26	)
Accrued expenses		(275	)
Operating lease liability		(384	)
Other liabilities		(34	)
Total liabilities assumed		(719	)
Net assets sold	$	24

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed

The following table summarizes the consideration transferred, the estimated fair value of the assets acquired, and liabilities assumed, at the acquisition date (in thousands):

	Amounts recognized as of the acquisition date
Fair value of consideration transferred
Common stock private placement	$	682
Warrants (included in derivative liabilities)		495
Total consideration transferred	$	1,177

Recognized amounts of identifiable assets acquired and liabilities assumed
Cash	$	750
Intangibles		145
Total assets acquired		895

Accounts payable and other accrued expenses		(20	)
Total identifiable net assets	$	875
Goodwill	$	302

Schedule of Basic and Diluted Loss Per Share

Below are basic and diluted loss per share data for the year ended December 31, 2025, which are in thousands except for share and per share data:

	Basic Calculation			Effect of Dilutive Warrant Securities		Diluted Calculation
Numerator:
Net loss	$	(10,364	)	$	-	$	(10,364	)
Deemed dividend related to inducement warrants		(6,719	)		-		(6,719	)
Net loss attributable to common stockholders	$	(17,083	)	$	-	$	(17,083	)

Denominator:
Number of shares used in per common share calculations:		2,773,518			-		2,773,518

Net loss per common share:
Net loss	$	(3.74	)	$	-	$	(3.74	)
Deemed dividend related to inducement warrants		(2.42	)		-		(2.42	)
Net loss attributable to common stockholders	$	(6.16	)	$	-	$	(6.16	)

Below are basic and diluted loss per share data for the year ended December 31, 2024, which are in thousands except for share and per share data:

	Basic Calculation			Effect of Dilutive Warrant Securities			Diluted Calculation
Numerator:
Net loss	$	(11,024	)	$	(291	)	$	(11,315	)
Deemed dividend related to inducement warrants		-			-			-
Net loss attributable to common stockholders	$	(11,024	)	$	(291	)	$	(11,315	)

Denominator:
Number of shares used in per common share calculations:		741,250			3,532			744,782

Net loss per common share:
Net loss	$	(14.87	)	$	(82.39	)	$	(15.19	)
Deemed dividend related to inducement warrants		-			-			-
Net loss attributable to common stockholders	$	(14.87	)	$	(82.39	)	$	(15.19	)

- Definition

Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-SubTopic 10
-Topic 360
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482099/360-10-50-3

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 360
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3A
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482099/360-10-50-3A

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 360
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3A
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482099/360-10-50-3A

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 45
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483475/205-20-45-11

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 3A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-3A

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-4A

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-4B

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5D
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-5D

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 360
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482099/360-10-50-3A

Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-SubTopic 20
-Topic 205
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-1

Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-3

+ Details

Accrued Liabilities (Tables)

12 Months Ended

Dec. 31, 2025

Payables and Accruals [Abstract]

Schedule of Accrued Liabilities

Accrued liabilities consisted of the following (in thousands):

Schedule of Accrued Liabilities

	2025		2024
	As of December 31,
	2025		2024
Payroll and related expenses	$	120	$	400
Accrued payables		50		178
Other		252		408
Accrued liabilities	$	422	$	986

Intangible Assets (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of intangible assets	$ 19	$ 5

- Definition

The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Subparagraph (b)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 18
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-18

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-11

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-24

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476148/220-40-50-12

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Name Accounting Standards Codification
-Section 55
-Paragraph 40
-SubTopic 30
-Topic 350
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482640/350-30-55-40

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482665/350-30-50-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482686/350-30-45-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476148/220-40-50-6

+ Details

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed (Details) - USD ($)	12 Months Ended
	Dec. 31, 2025	Feb. 19, 2025	Dec. 31, 2024
Restructuring Cost and Reserve [Line Items]
Total consideration transferred	$ 1,177,000
Cash	750,000	$ 4,000
Intangibles	145,000
Total assets sold	895,000	$ 743,000
Accounts payable and other accrued expenses	(20,000)
Total identifiable net assets	875,000
Goodwill	302,000
Common Stock Private Placement [Member]
Restructuring Cost and Reserve [Line Items]
Total consideration transferred	682,000
Warrants [Member]
Restructuring Cost and Reserve [Line Items]
Total consideration transferred	$ 495,000

Schedule of Components of Property and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 3,528	$ 3,970
Less: accumulated depreciation	(3,052)	(3,048)
Property and equipment, net	476	922
Manufacturing Lab Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	1,783	2,220
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	989	968
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	674	664
Furniture and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 82	$ 118

Organization and Summary of Significant Accounting Policies (Details Narrative) - USD ($)				1 Months Ended	12 Months Ended
	Oct. 03, 2025	Jul. 01, 2025	May 28, 2024	Oct. 31, 2025	Dec. 31, 2025	Dec. 31, 2024
Product Information [Line Items]
Total assets					$ 9,506,000	$ 9,413,000
Reverse stock split, description			1 for 200 reverse stock split
Sublease income				$ 29,200
Accounts receivable						11,000
Leasehold improvements useful lives					Leasehold improvements are amortized over the shorter of their estimated useful lives or the related lease term, generally five years.
Advertising costs					$ 0	$ 0
Warrants to purchase exercise price per share					$ 0.01	$ 0.01
Goodwill					$ 302,000
Number of potentially dilutive securities					3,300,000	200,000
Sinaptic Surgical [Member]
Product Information [Line Items]
Warrants to purchase shares		325,000
Warrants to purchase exercise price per share		$ 6.30
Sinaptic Holdings LLC [Member]
Product Information [Line Items]
Warrants to purchase shares		216,450
Warrants to purchase exercise price per share		$ 3.465
Minimum [Member]
Product Information [Line Items]
Sublease income				9,700
Property and equipment, estimated useful lives					3 years
Maximum [Member]
Product Information [Line Items]
Sublease income				11,300
Property and equipment, estimated useful lives					5 years
Revenue Benchmark [Member] \| Customer Concentration Risk [Member] \| Three Commercial Customer and Government Agencies [Member]
Product Information [Line Items]
Concentration risk percentage					72.00%
Accounts Receivable [Member] \| Customer Concentration Risk [Member] \| Three Commercial Customer and Government Agencies [Member]
Product Information [Line Items]
Concentration risk percentage					80.00%
2025 ATM Agreement [Member]
Product Information [Line Items]
Offering price	$ 6,413,876
Warrants to purchase exercise price per share	$ 0.01
Armor Facility [Member]
Product Information [Line Items]
Sublease income				$ 1,000,000.0
Revision of Prior Period, Adjustment [Member]
Product Information [Line Items]
Total assets					$ 250,000

Schedule of Basic and Diluted Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net loss, basic calculation	$ (10,364)	$ (11,024)
Net loss, effect of dilutive warrant securities		(291)
Net loss, diluted calculation	(10,364)	(11,315)
Deemed dividend related to warrant inducement, basic calculation	(6,719)
Deemed dividend related to warrant inducement, effect of dilutive warrant securities
Deemed dividend related to warrant inducement, diluted calculation	(6,719)
Net loss attributable to common stockholders, basic calculation	(17,083)	(11,024)
Net loss attributable to common stockholders, effect of dilutive warrant securities		(291)
Net loss attributable to common stockholders, diluted calculation	$ (17,083)	$ (11,315)
Number of shares used in per common share calculations: basic calculation	2,773,518	741,250
Number of shares used in per common share calculations: effect of dilutive warrant securities		3,532
Number of shares used in per common share calculations: diluted calculation	2,773,518	744,782
Net loss per common share: basic calculation	$ (3.74)	$ (14.87)
Net loss per common share: effect of dilutive warrant securities		(82.39)
Net loss per common share: diluted calculation	(3.74)	(15.19)
Deemed dividend related to warrant inducement, basic calculation	(2.42)
Deemed dividend related to warrant inducement, diluted calculation	(2.42)
Net loss attributable to common stockholders, basic calculation	(6.16)	(14.87)
Net loss attributable to common stockholders, diluted calculation	$ (6.16)	$ (15.19)

Organization and Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2025

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization and Summary of Significant Accounting Policies

1. Organization and Summary of Significant Accounting Policies

The consolidated financial statements include the accounts of SINTX Technologies, Inc. (“SINTX”) and its wholly-owned subsidiaries, SINTX Armor, Inc. (“SINTX Armor”), SINTX Agribiotech, Inc., Sinaptic Surgical, LLC, and Technology Assessment and Transfer, Inc. (TA&T) through February 19, 2025 (see Note 1), which are collectively referred to as “we” or the “Company.” SINTX Technologies is an advanced ceramics company formed in December 1996 that develops and commercializes materials, components, and technologies for medical, industrial and agribiotech applications. SINTX provides biomedical solutions for medical devices specializing in silicon nitride (Si₃N₄) for musculoskeletal and antipathogenic applications. SINTX is a global leader in the research, development, and manufacturing of silicon nitride, and its products have been implanted in humans since 2008.

SINTX Core Business

Biomedical Applications: Since its inception, SINTX has been focused on medical grade silicon nitride. SINTX biomedical products have been shown to be biocompatible, bioactive, antipathogenic, and to have superb bone affinity. Spinal implants made from SINTX silicon nitride have been successfully implanted in humans since 2008 in the U.S., Europe, South America and Asia. This established use, along with its inherent resistance to bacterial adhesion and bone affinity suggests that it may also be suitable in other fusion device applications such as arthroplasty implants, foot wedges, and dental implants. More recently, in October 2025, SINTX received U.S. Food and Drug Administration (FDA) 510(k) clearance for the SiNAPTIC® Foot & Ankle Osteotomy Wedge System, enabling SINTX’s commercial entry into reconstructive foot and ankle surgery in the United States.

Antipathogenic Applications: SINTX believes that by incorporating its unique composition of silicon nitride antipathogenic powder into products such as face masks, drapes, filters, sutures, and wound care devices, it is possible to manufacture surfaces that inactivate pathogens, thereby limiting the spread of infection and disease. We presently manufacture advanced ceramic powders and components in our manufacturing facilities based in Salt Lake City, Utah.

The SINTX Salt Lake City facility is registered with the FDA, is cGMP and ANVISA RDC 665 compliant, as well as being ISO 9001:2015, ISO 13485:2016 certified, and AS9100D certified. The Company’s products are primarily sold in the United States.

Basis of Presentation and Principles of Consolidation

These consolidated financial statements have been prepared by management in accordance with the rules and regulations of the United States Securities and Exchange Commission (“SEC”) and include all assets and liabilities of the Company.

Operating Segments

The Company operates as one operating segment.  Operating segments are defined as components of an entity for which separate financial information is regularly evaluated by the chief operating decision maker (“CODM”), which is the Company’s Chief Executive Officer, in deciding how to allocate resources and assess performance.  The Company’s CODM evaluates financial information and resources and assesses the performance of these resources on a consolidated basis.  There is no expense or asset information that is supplemental to information disclosed within the consolidated financial statements, that is regularly provided to the CODM.  The allocation of resources and assessment of performance of the operating segment is based on consolidated net loss and functional expenses as reported on our consolidated statements of operations.  Because the Company operates as one operating segment, financial segment information, including expense and asset information, can be found in the consolidated financial statements.

Reclassification

Certain other prior period balances have been reclassified to conform to the current period presentation, including the reclassification of $250,000 from prepaid expenses and other current assets to other long-term assets, with no effect on previously reported total assets, stockholders’ equity, or results of operations.

Reverse Stock Split

On May 28, 2024, the Company effected a 1 for 200 reverse stock split of the Company’s common stock. The par value and the authorized shares of the common and preferred stock were not adjusted as a result of the reverse stock split. All common stock shares, equivalents, and per-share amounts for all periods presented in these consolidated financial statements have been adjusted retroactively to reflect the reverse stock split.

Liquidity and Capital Resources

The consolidated financial statements have been prepared assuming the Company will continue to operate as a going concern. To date, the Company’s operations have been principally financed from proceeds from the issuance of preferred and common stock and, to a lesser extent, cash generated from product sales. It is anticipated that the Company will continue to generate operating losses and use cash in operations. The Company’s continuation as a going concern is dependent upon its ability to increase sales, decrease expenses and raise additional funding. We continue to seek opportunities to raise additional funding through equity and/or debt financing. However, such funding is not guaranteed and may not be available to the Company on favorable terms and may involve restrictive covenants. If the Company is not able to obtain additional debt or equity financing, the impact on the Company will be material and adverse.

The board of directors, together with management, remains focused on advancing the Company’s business strategy and focus. We are concentrating our resources on high-growth areas within the healthcare sector where our proprietary materials and technologies—such as silicon nitride—provide a distinct competitive advantage due to their unique strength, durability, and biocompatibility. Through this transformation, as demonstrated by the recent FDA 510(k) clearance of our SiNAPTIC® Foot & Ankle Osteotomy Wedge System, our aim is to deliver meaningful innovations to the medical community. By focusing on partnerships and collaborations with healthcare institutions and industry leaders, SINTX is positioned to expand its footprint in the medical device sector and drive shareholder value through sustainable, high-impact innovations.

On August 8, 2024, the board of directors approved a plan to implement a Company-wide reduction in the workforce. This decision was part of the Company’s ongoing strategic review of its operations aimed at improving operational efficiency and reducing costs.

On August 12, 2024, the board of directors approved a plan to cease efforts to make the armor plant operational. This decision was made to streamline operations and focus on core business areas that align with the Company’s long-term strategic goals. The armor plant had not been fully operational since the acquisition of the armor equipment in July 2021 and had been completely shut down since October 2023.

As discussed in Note 1 to the consolidated financial statements, on February 19, 2025, the Company sold to Tethon all the issued and outstanding shares of TA&T in exchange for the assumption by Tethon of the outstanding liabilities of TA&T.

As discussed in further detail above, in October 2025, the Company received FDA 510(k) clearance for a new foot and ankle osteotomy wedge system, enabling SINTX’s commercial entry into reconstructive foot and ankle surgery in the United States. Revenue is expected to begin during the first half of 2026.

As discussed in Note 8 to the consolidated financial statements, in October 2025, the Company entered into the 2025 ATM Agreement to sell shares of its common stock from time to time, through an “at the market offering” program, having an aggregate offering price of $6.4 million.

As discussed in Note 13 to the consolidated financial statements, in October 2025, the Company entered into a sublease agreement to lease the SINTX armor facility to a third party, that is expected to save the Company approximately $1.0 million over the sublease term.

While management has implemented plans intended to mitigate these conditions, management has concluded that substantial doubt exists about the Company’s ability to continue as a going concern for 12 months from the date these consolidated financial statements are issued. The consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties.

Use of Estimates

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the period. Actual results could differ from those estimates. As of December 31, 2025, the most significant estimate relates to derivative liabilities relating to common stock warrants.

Concentrations of Credit Risk and Significant Customers

Financial instruments which potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, and notes receivable. Because the financial institution that the Company currently uses does not participate in the Certificate of Deposit Account Registry Service (“CDARS”), the Company does not presently have a program to limit its exposure to credit loss. The Company’s deposits, at times, may exceed federally insured limits.

As of and for the year ended December 31, 2025, five commercial customers and government agencies represent 72% of the Company’s total revenues and 80% of the Company’s total accounts receivable.

Revenue Recognition

The Company derived its product revenue primarily from the sale of aerospace components and spinal fusion products. The aerospace components are key ceramic aircraft engine components sold to a leading manufacturer of aerospace components and systems by which the Company has entered into a 10-year, long-term agreement. The spinal fusion products are used in the treatment of spine disorders and sold to CTL Medical, with whom the Company signed a 10-year exclusive sales agreement in October 2018. The Company also records revenue from grants, contracts, and awards provided by government agencies. The Company is currently pursuing other sales opportunities for silicon nitride outside the spinal fusion application.

Revenue is recognized when control of the goods or services promised under the contract is transferred to the customer either at a point in time (e.g., upon delivery) or over time (e.g., as performed under the contract). The Company accounts for a contract when it has approval and commitment from both parties, the rights and payment terms of the parties are identified, the contract has commercial substance and collectability of consideration is probable. Contracts are reviewed to determine whether the contract contains one or multiple performance obligations. A performance obligation is a promise to transfer a distinct good or service to a customer and represents the unit of accounting for revenue recognition. For contracts with multiple performance obligations, the expected consideration, or the transaction price, is allocated to each performance obligation identified in the contract based on the relative standalone selling price of each performance obligation. Revenue is then recognized for the transaction price allocated to the performance obligation when control of the promised goods or services underlying the performance obligation is transferred. Contract consideration is not adjusted for the effects of a significant financing component when, at contract inception, the period between when control transfers and when the customer will pay for that good or service is one year or less. Contact modifications that add distinct goods or services at the standalone selling price are accounted for as separate contracts. The transaction price for our contracts reflects our estimate of returns, rebates and discounts, which historically have not been significant. Amounts billed to customers for shipping and handling are included in the transaction price and generally are not treated as separate performance obligations as these costs fulfill a promise to transfer the product to the customer. The Company employs salespeople to actively seek additional customers; there are no incremental costs for obtaining customers that need to be capitalized.

The Company recognizes revenue from sales of products at the time the product is shipped.

Revenues from grants, contracts, and awards provided by governmental agencies are recorded based upon the terms of the specific agreements, which generally provide that revenue is earned when the allowable costs specified in the applicable agreement have been incurred or a milestone has been met. Cash received from federal grants, contracts, and awards can be subject to audit by the grantor and, if the examination results in a disallowance of any expenditure, repayment could be required. The duration of the government grants, contracts, and awards varies by government entity as well as phase level. The general duration period during 2025 is approximately one year.

Grant, contract, and award receivables relate to allowable amounts expended or otherwise incurred or earned in connection with the terms of a grant, contract, or award and for which reimbursement has not yet taken place. As of December 31, 2025, government grants, contracts, and awards accounted for approximately $11,000 in accounts receivable. To be eligible to receive moneys from government agencies the Company must meet commitments as outlined in the grant, contract, and award agreements.

Costs of Revenue

The expenses that are included in costs of revenue associated with product sales include all raw material and in-house manufacturing costs for the products we manufacture.

Cash and Cash Equivalents

The Company considers all cash on deposit, money market accounts and highly-liquid debt instruments purchased with original maturities of three months or less to be cash and cash equivalents.

Inventories

Inventories are stated at the lower of cost or net realizable value, with cost for manufactured inventory determined under the standard costs, which approximate actual costs, determined on the first-in first-out (“FIFO”) method. Manufactured inventory consists of raw material, direct labor and manufacturing overhead cost components. The Company reviews the carrying value of inventory on a periodic basis for excess or obsolete items, and records any write-down as a cost of revenue, as necessary. Inventory that is not expected to be utilized within 12 months of December 31, 2025, and 2024, respectively is recorded as long term.

Property and Equipment

Property and equipment, including leasehold improvements, are stated at cost, less accumulated depreciation and amortization. Property and equipment are depreciated using the straight-line method over the estimated useful lives of the assets, which range from three3 to five years. Leasehold improvements are amortized over the shorter of their estimated useful lives or the related lease term, generally five years.

The Company reviews the carrying value of the Company’s property and equipment that are held and used in the Company’s operations for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of these assets is determined based upon expected undiscounted future net cash flows from the operations to which the assets relate, utilizing management’s best estimate, assumptions, and projections at the time. If the carrying value is determined to be unrecoverable from future operating cash flows, the asset is deemed impaired, and an impairment charge would be recognized to the extent the carrying value exceeded the estimated fair value of the asset. The Company estimates the fair value of assets based on the estimated future discounted cash flows of the asset.

Leases

The Company determines if an arrangement is a lease at inception. Operating leases are in operating lease right of use asset and operating lease liability in our consolidated balance sheet. Finance leases, if any, are included in property and equipment in our consolidated balance sheet. Leases with an initial term of 12 months or less are not presented on the consolidated balance sheet. The Company accounts for lease payments separately from non-lease components. The depreciable life of the asset and leasehold improvement are limited by the expected lease term.

Account and Other Receivables and Allowance for Credit Losses

Financial assets, which potentially subject the Company to credit losses, consist primarily of receivables. We measure expected credit losses of financial assets based on historical loss and other information available to management using type of receivable (commercial, grants or contracts, retainage, or other) and different aging categories (less than 90 days past due, over 90 days past due, over 180 days past due, and financially troubled customers). These expected losses are recorded to an allowance for credit losses valuation account that is deducted from receivables to present the net amount expected to be collected on the financial asset on the consolidated balance sheet. Management believes that the historical loss information it has compiled is a reasonable basis on which to determine expected credit losses for trade receivables held as of December 31, 2025, because the composition of the trade receivables as of that date is consistent with that used in developing the historical credit-loss percentages (i.e., the similar risk characteristics of its customers and its lending practices have not changed significantly over time).

Long Lived Intangible Assets

The Company evaluates the carrying value of intangibles when events or changes in circumstances indicate that the carrying value may not be recoverable. Factors the Company considers important which could trigger an impairment review include, but are not limited to, significant under-performance relative to historical or projected future operating results, significant changes in the manner of its use of acquired assets or its overall business strategy, and significant industry or economic trends. The Company amortizes definite-lived intangible assets on a straight-line basis over their useful lives. The Company recorded no impairment loss for definite-lived intangible assets during the year ended December 31, 2025.

Derivative Liabilities

Derivative liabilities include the fair value of certain common stock warrants, which are initially recorded at fair value and are required to be re-measured to fair value at each reporting period. The change in fair value of the instruments is recognized as a component of other income (expense) in the Company’s consolidated statements of operations until the instruments settle, expire or are no longer classified as derivative liabilities. The Company estimates the fair value of these instruments primarily using Monte-Carlo valuation models. The significant assumptions used in estimating the fair value include the exercise price, volatility of the stock underlying the instrument, risk-free interest rate, estimated fair value of the stock underlying the instrument and the estimated life of the instrument.

Research and Development

All research and development costs, including those funded by third parties, are expensed as incurred. Research and development costs consist of engineering, product development, test-part manufacturing, testing, developing and validating the manufacturing process, and regulatory related costs. Research and development expenses also include employee compensation, employee and nonemployee stock-based compensation, supplies and materials, consultant services, and travel and facilities expenses related to research activities.

We expect to incur additional research and development costs as we continue to develop new biomedical and antipathogenic products.

Advertising Costs

Advertising costs are expensed as incurred. The primary component of the Company’s advertising expenses is advertising in trade periodicals. Advertising costs were not significant for each of the years ended December 31, 2025 and 2024.

Income Taxes

The Company recognizes deferred tax assets and liabilities for the future tax consequences attributable to the differences between the financial statement carrying value of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the fiscal year in which those temporary differences are expected to be recovered or settled. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.

The Company operates in various tax jurisdictions and is subject to audit by various tax authorities. The Company provides for tax contingencies whenever it is deemed probable that a tax asset has been impaired, or a tax liability has been incurred for events such as tax claims or changes in tax laws. Tax contingencies are based upon their technical merits relative tax law and the specific facts and circumstances as of each reporting period. Changes in facts and circumstances could result in material changes to the amounts recorded for such tax contingencies.

The Company recognizes uncertain income tax positions taken on income tax returns at the largest amount that is more-likely than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained.

The Company’s policy for recording interest and penalties associated with uncertain tax positions is to record such items as a component of our income tax provision. For the years ended December 31, 2025 and 2024, the Company did not record any material interest income, interest expense or penalties related to uncertain tax positions or the settlement of audits for prior periods.

Stock-Based Compensation

The Company measures stock-based compensation expense related to employee stock-based awards based on the estimated fair value of the awards as determined on the date of grant and is recognized as expense over the remaining requisite service period. The Company utilizes the Black-Scholes-Merton option pricing model to estimate the fair value of employee stock options. The Black-Scholes-Merton model requires the input of subjective assumptions, including the estimated fair value of the Company’s common stock on the date of grant, the expected term of the stock option, and the expected volatility of the Company’s common stock over the period equal to the expected term of the grant. The Company estimates forfeitures at the date of grant and revises the estimates, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The Company accounts for stock options to purchase shares of stock that are issued to non-employees based on the estimated fair value of such instruments using the Black-Scholes-Merton option pricing model.

Disposition of TA&T

On February 19, 2025, the Company entered into an Entity Acquisition Agreement (the “Agreement”) with Tethon Corporation (“Tethon”), pursuant to which the Company sold to Tethon all the issued and outstanding shares of TA&T in exchange for the assumption by Tethon of the outstanding liabilities of TA&T. The disposal did not represent a strategic shift that will have a major effect on the Company’s operations and financials and, therefore, did not qualify for discontinued operations treatment under ASC 205-20.

The following table summarizes the carrying amounts of the major classes of assets and liabilities of TA&T at the date of sale that were transferred to the Tethon (in thousands):

	February 19, 2025
Cash and cash equivalents	$	4
Inventories		8
Accounts receivable		91
Right of use asset		376
Property and equipment, net		248
Other assets		16
Total assets sold		743
Accounts payable		(26	)
Accrued expenses		(275	)
Operating lease liability		(384	)
Other liabilities		(34	)
Total liabilities assumed		(719	)
Net assets sold	$	24

No consideration was paid other than the assumption by Tethon of the above liabilities. No significant transaction costs were incurred. No earnout or other contingent consideration arrangements were included in the Agreement.

Business Combination

On July 1, 2025, the Company entered into an Asset Purchase Agreement with Sinaptic Surgical, LLC (“Sinaptic Surgical”) and Sinaptic Holdings, LLC (“Holdings”), pursuant to which the Company agreed to purchase substantially all the assets and assume certain liabilities of Sinaptic Surgical. As consideration for the purchase of the assets under the Asset Purchase Agreement, the Company agreed to issue to Sinaptic Surgical warrants to purchase 325,000 shares of the Company’s common stock (the “Warrants”). The Warrants expire five years from the date of issue and have an exercise price of $6.30 per share. The Warrants will become exercisable upon the achievement of certain milestones prior to the expiration of the Warrants. In connection with the Asset Purchase Agreement, Sinaptic Surgical purchased 216,450 shares of the Company’s common stock at a purchase price of $3.465 per share in a private placement.

The fair value for the acquired intangible asset was estimated utilizing the income approach, which involves the use of significant estimates and assumptions including projected revenue growth rates, projected earnings, and discount rates.

The following table summarizes the consideration transferred, the estimated fair value of the assets acquired, and liabilities assumed, at the acquisition date (in thousands):

	Amounts recognized as of the acquisition date
Fair value of consideration transferred
Common stock private placement	$	682
Warrants (included in derivative liabilities)		495
Total consideration transferred	$	1,177

Recognized amounts of identifiable assets acquired and liabilities assumed
Cash	$	750
Intangibles		145
Total assets acquired		895

Accounts payable and other accrued expenses		(20	)
Total identifiable net assets	$	875
Goodwill	$	302

The Company recognized goodwill of $302,000, which reflects the future benefits of certain synergies, and regulatory and commercialization strategies. Acquired intangible assets are being amortized over the estimated useful life of five years on a straight-line basis.

Net Loss Per Share – Basic and Diluted

Basic net income (loss) per share is calculated by dividing the net income (loss) by the weighted-average number of shares of common stock outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock equivalents outstanding for the period that are determined to be dilutive. Common stock equivalents are primarily comprised of preferred stock, options and warrants for the purchase of common stock The Company had potentially dilutive securities, totaling approximately 3.3 million and 0.2 million shares of common stock as of December 31, 2025 and 2024, respectively.

Below are basic and diluted loss per share data for the year ended December 31, 2025, which are in thousands except for share and per share data:

	Basic Calculation			Effect of Dilutive Warrant Securities		Diluted Calculation
Numerator:
Net loss	$	(10,364	)	$	-	$	(10,364	)
Deemed dividend related to inducement warrants		(6,719	)		-		(6,719	)
Net loss attributable to common stockholders	$	(17,083	)	$	-	$	(17,083	)

Denominator:
Number of shares used in per common share calculations:		2,773,518			-		2,773,518

Net loss per common share:
Net loss	$	(3.74	)	$	-	$	(3.74	)
Deemed dividend related to inducement warrants		(2.42	)		-		(2.42	)
Net loss attributable to common stockholders	$	(6.16	)	$	-	$	(6.16	)

Below are basic and diluted loss per share data for the year ended December 31, 2024, which are in thousands except for share and per share data:

	Basic Calculation			Effect of Dilutive Warrant Securities			Diluted Calculation
Numerator:
Net loss	$	(11,024	)	$	(291	)	$	(11,315	)
Deemed dividend related to inducement warrants		-			-			-
Net loss attributable to common stockholders	$	(11,024	)	$	(291	)	$	(11,315	)

Denominator:
Number of shares used in per common share calculations:		741,250			3,532			744,782

Net loss per common share:
Net loss	$	(14.87	)	$	(82.39	)	$	(15.19	)
Deemed dividend related to inducement warrants		-			-			-
Net loss attributable to common stockholders	$	(14.87	)	$	(82.39	)	$	(15.19	)

Recent Accounting Pronouncements

ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures

In December 2023, the FASB issued ASU 2023-09 “Income Taxes (Topic 740): Improvements to Income Tax Disclosures” on the topic of income taxes. The standard requires additional disclosure for income taxes. These requirements include: (i) requiring a public entity to disclose specific categories in the rate reconciliation; (ii) disclosure of additional information for reconciling items that meet a quantitative threshold (if the effect of those reconciling items is equal to or greater than 5% of the amount computed by multiplying pretax income or loss by the applicable statutory income tax rate); (iii) annual disclosure of the amount of income taxes paid (net of refunds received) disaggregated by federal (national), state, and foreign taxes; (iv) annual disclosure of the amount of income taxes paid (net of refunds received) disaggregated by individual jurisdictions in which income taxes paid (net of refunds received) is equal to or greater than 5% of total income taxes paid (net of refunds received); (v) annual disclosure of income (or loss) from continuing operations before income tax expense (or benefit) disaggregated between domestic and foreign; and (vi) annual disclosure of income tax expense (or benefit) from continuing operations disaggregated by federal (national), state, and foreign. For public entities, the guidance is effective for annual periods beginning after December 15, 2024. The Company prospectively adopted this guidance in fiscal 2025, requiring updates to the related disclosures, yet with no material effect on the consolidated financial statements.

ASU 2024-03, Income Statement—Reporting Comprehensive Income (Topic 220): Disaggregation of Income Statement Expenses

In November 2024, the FASB issued ASU No. 2024-03, “Income Statement—Reporting Comprehensive Income (Topic 220): Disaggregation of Income Statement Expenses,” which requires public business entities, such as the Company, to provide disaggregated disclosure of specific natural expense categories underlying certain income statement expense line items in the notes to the financial statements. The standard identifies five required natural expense categories for disaggregation—employee compensation, depreciation, amortization, inventory expense, and other manufacturing expenses—along with a residual “other” category for remaining amounts within relevant expense captions (e.g., cost of sales, selling, general and administrative expenses). ASU 2024-03 does not alter the expense captions presented on the face of the income statement but enhances footnote disclosures to improve transparency. The standard is effective for annual periods beginning after December 15, 2026, with early adoption permitted, and must be applied prospectively, though retrospective application is optional. An update in ASU 2025-01 clarified that interim period disclosures are not required until annual periods beginning after December 15, 2027. The Company is in the process of evaluating the impact of ASU 2024-03 on its consolidated financial statements. We expect adoption to necessitate modifications to our financial reporting processes and systems to capture and disclose the required disaggregated expense information in the footnotes. Management anticipates that this will enhance the granularity of expense disclosures but does not expect a material effect on our reported financial position or results of operations. We are reviewing our current expense classification practices and data collection capabilities to ensure compliance with the new requirements upon adoption.

The Company has determined that recently issued accounting standards, other than the above discussed, will not have a material impact on its consolidated financial position, results of operations or cash flows.

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2025

Income Tax Disclosure [Abstract]

Schedule of Tax Based on Income

Taxes based on income were as follows:

Schedule of Tax Based on Income

		2025		2024
		December 31,
		2025		2024

Current:	$	-	$	-
U.S. federal tax		-		-
State taxes	$	-	$	-

Deferred:
U.S. federal tax	$	-	$	-
State tax		-		-
	$	-	$	-

Provision for income taxes	$	-	$	-

Schedule of Significant Components of Deferred Tax Assets and Liabilities

Deferred taxes reflect the temporary differences between the amounts at which assets and liabilities are recorded for financial reporting purposes and the amounts utilized for tax purposes. The primary components of the temporary differences that gave rise to our deferred tax assets and liabilities were as follows:

	2025			2024
	December 31,
	2025			2024
Deferred tax assets:
Net operating loss carryforwards	$	59,358		$	57,763
Stock-based compensation		3,690			3,192
Federal R&D credit		2,120			2,222
Impairment		1,146			1,148
Accrued expenses		-			53
Capitalized research expenses		2,217			3,145
Intangibles		186			237
Right of use asset/liabilities		32			32
Depreciation		243			-
Other		1			15
Total deferred tax assets		68,993			67,807
Deferred tax liabilities:
Depreciation		-			(431	)

Total deferred tax liabilities		-			(431	)
Less valuation allowance		(68,993	)		(67,376	)
Net deferred tax liability	$	-		$	-

Schedule of Operating Losses and Tax Credit Carryforwards

(in millions)	Operating Losses		Tax Credits
Year of expiry:
2026	$	5.1	$	0.2
2027		11.5		0.2
2028		15.3		0.5
2029		15.9		0.3
2030-2037		114.8		0.9
Indefinite life / no expiry		75.3		0.0
Total	$	237.9	$	2.1

Schedule of Reconciliation Statutory Federal Income Tax Provision to Actual Income Tax Benefit

The principal items accounting for the difference between taxes computed at the U.S. federal statutory rate and taxes recorded were as follows (in thousands) after the adoption of ASU 2023-09:

	2025			2024
	Year Ended December 31, 2025
	Amount			Percent

U.S. federal statutory tax rate	$	(2,176	)		(21.00	)%
State and local income taxes, net of federal income tax effect		-			0.00	%
Foreign tax effects		-			0.00	%
Effect of changes in tax laws or rates enacted in the current period		-			0.00	%
Effect of cross-border tax laws		-			0.00	%
Tax credits:
Research and development tax credits		102			0.99	%
Changes in valuation allowances		1,617			15.60	%
Nontaxable or nondeductible items:
Change in value – warrants		26			0.25	%
Other		6			0.06	%
Changes in unrecognized tax benefits		-			0.00	%
Other adjustments		425			4.10	%
Effective tax rate	$	-			-

The principal items accounting for the difference between taxes computed at the U.S. federal statutory rate and taxes recorded were as follows (in thousands) for the year prior to the adoption of ASU 2023-09:

	Year Ended December 31, 2024

Pre-tax book income tax at statutory rate	$	(2,315	)
State taxes, net of federal benefit		(482	)
Return to provision		-
Equity related expenses		(614	)
Deferred adjustments		-
Expiration of R&D credits		-
Change in valuation allowance		3,409
Other		2
Total income tax expense	$	-

The following is a reconciliation of the expected statutory federal income tax rate to the actual effective tax rate (in thousands):

	2024
	Year Ended December 31, 2024
Federal statutory rate		(21.0	)%
State taxes, net of federal benefit		(4.3	)%
Return to provision		0.0	%
Equity related expenses		(5.6	)%
Deferred adjustments		0.0	%
Expiration of R&D credits		0.0	%
Change in valuation allowance		30.9	%
Total income tax expense		0.0	%

Schedule of Income Loss Before Taxes

Income/(loss) before taxes from our U.S. operations was follows:

Schedule of Income Loss Before Taxes

	2025			2024
U.S.	$	(10,364	)	$	(11,024	)
Foreign		-			-
Income before taxes	$	(10,364	)	$	(11,024	)

Schedule of Income Taxes Paid

	Year Ended December 31, 2025
Federal	$	-
State and local		-
Foreign		-
Total income taxes paid (net of refunds received)	$	-

Property and Equipment (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Property, Plant and Equipment [Line Items]
Depreciation expense	$ 319	$ 842
SINTX Armor Inc [Member]
Property, Plant and Equipment [Line Items]
Impairment of property and equipment		$ 3,700

Schedule of Assumptions Used in Estimating Fair Value (Details) - Common Stock Warrants [Member] - Black-Scholes-Merton Valuation Model [Member]	Dec. 31, 2025	Dec. 31, 2024
Measurement Input, Risk Free Interest Rate [Member] \| Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants measurement input	3.42	4.12
Measurement Input, Risk Free Interest Rate [Member] \| Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants measurement input	3.65	4.35
Measurement Input, Expected Term [Member] \| Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Weighted-average expected life	1 month 9 days	1 month 6 days
Measurement Input, Expected Term [Member] \| Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Weighted-average expected life	4 years 5 months 23 days	4 years 1 month 2 days
Measurement Input, Expected Dividend Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants measurement input
Measurement Input, Option Volatility [Member] \| Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants measurement input	115.0	140.0
Measurement Input, Option Volatility [Member] \| Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants measurement input	175.0	210.0

Fair Value Measurements (Tables)

12 Months Ended

Dec. 31, 2025

Fair Value Disclosures [Abstract]

Schedule of Financial Liabilities Measured at Fair Value on Recurring Basis by Level Within Fair Value Hierarchy

	Fair Value Measurements as of December 31, 2025 (in thousands)
Description	Level 1		Level 2		Level 3		Total
Derivative liabilities
Common stock warrants	$	-	$	-	$	827	$	827

	Fair Value Measurements as of December 31, 2024 (in thousands)
Description	Level 1		Level 2		Level 3		Total
Derivative liabilities
Common stock warrants	$	-	$	-	$	208	$	208

Schedule of Fair Value Measurement Hierarchy of Derivative Liability

	Common Stock Warrants
Balance as of December 31, 2023	$	304
Issuance of derivatives		3,366
Exercise of warrants		(1	)
Change in fair value		(3,475	)
Other		14
Balance as of December 31, 2024	$	208
Issuance of derivatives		495
Change in fair value		124
Balance as of December 31, 2025	$	827

Schedule of Assumptions Used in Estimating Fair Value

The assumptions used in estimating the common stock warrant liability using the Monte Carlo simulation valuation model as of December 31, 2025 and 2024 were as follows:

	December 31, 2025			December 31, 2024
Weighted-average risk-free interest rate		3.42-3.65	%		4.12-4.35	%
Weighted-average expected life (in years)		0.11-4.48			0.10-4.09
Expected dividend yield		-	%		-	%
Weighted average expected volatility		115.0-175.0	%		140.0%-210.0	%

Related Party Transactions (Details Narrative) - Research Collaboration Agreement [Member]	12 Months Ended
	Dec. 31, 2025 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payment of research fund	$ 500,000
Prepaid Expenses And Other Current Asset [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research fund remaining prepaid balance	$ 0

Organization and Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2025

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Basis of Presentation and Principles of Consolidation

Basis of Presentation and Principles of Consolidation

Operating Segments

Operating Segments

Reclassification

Reclassification

Reverse Stock Split

Reverse Stock Split

Liquidity and Capital Resources

Liquidity and Capital Resources

Use of Estimates

Use of Estimates

Concentrations of Credit Risk and Significant Customers

Concentrations of Credit Risk and Significant Customers

As of and for the year ended December 31, 2025, five commercial customers and government agencies represent 72% of the Company’s total revenues and 80% of the Company’s total accounts receivable.

Revenue Recognition

Revenue Recognition

The Company recognizes revenue from sales of products at the time the product is shipped.

Costs of Revenue

Costs of Revenue

The expenses that are included in costs of revenue associated with product sales include all raw material and in-house manufacturing costs for the products we manufacture.

Cash and Cash Equivalents

Cash and Cash Equivalents

The Company considers all cash on deposit, money market accounts and highly-liquid debt instruments purchased with original maturities of three months or less to be cash and cash equivalents.

Inventories

Inventories

Property and Equipment

Property and Equipment

Leases

Leases

Account and Other Receivables and Allowance for Credit Losses

Account and Other Receivables and Allowance for Credit Losses

Long Lived Intangible Assets

Long Lived Intangible Assets

Derivative Liabilities

Derivative Liabilities

Research and Development

Research and Development

We expect to incur additional research and development costs as we continue to develop new biomedical and antipathogenic products.

Advertising Costs

Advertising Costs

Income Taxes

Income Taxes

Stock-Based Compensation

Stock-Based Compensation

Disposition of TA&T

Disposition of TA&T

The following table summarizes the carrying amounts of the major classes of assets and liabilities of TA&T at the date of sale that were transferred to the Tethon (in thousands):

	February 19, 2025
Cash and cash equivalents	$	4
Inventories		8
Accounts receivable		91
Right of use asset		376
Property and equipment, net		248
Other assets		16
Total assets sold		743
Accounts payable		(26	)
Accrued expenses		(275	)
Operating lease liability		(384	)
Other liabilities		(34	)
Total liabilities assumed		(719	)
Net assets sold	$	24

Business Combination

Business Combination

The following table summarizes the consideration transferred, the estimated fair value of the assets acquired, and liabilities assumed, at the acquisition date (in thousands):

	Amounts recognized as of the acquisition date
Fair value of consideration transferred
Common stock private placement	$	682
Warrants (included in derivative liabilities)		495
Total consideration transferred	$	1,177

Recognized amounts of identifiable assets acquired and liabilities assumed
Cash	$	750
Intangibles		145
Total assets acquired		895

Accounts payable and other accrued expenses		(20	)
Total identifiable net assets	$	875
Goodwill	$	302

Net Loss Per Share – Basic and Diluted

Net Loss Per Share – Basic and Diluted

Below are basic and diluted loss per share data for the year ended December 31, 2025, which are in thousands except for share and per share data:

	Basic Calculation			Effect of Dilutive Warrant Securities		Diluted Calculation
Numerator:
Net loss	$	(10,364	)	$	-	$	(10,364	)
Deemed dividend related to inducement warrants		(6,719	)		-		(6,719	)
Net loss attributable to common stockholders	$	(17,083	)	$	-	$	(17,083	)

Denominator:
Number of shares used in per common share calculations:		2,773,518			-		2,773,518

Net loss per common share:
Net loss	$	(3.74	)	$	-	$	(3.74	)
Deemed dividend related to inducement warrants		(2.42	)		-		(2.42	)
Net loss attributable to common stockholders	$	(6.16	)	$	-	$	(6.16	)

Below are basic and diluted loss per share data for the year ended December 31, 2024, which are in thousands except for share and per share data:

	Basic Calculation			Effect of Dilutive Warrant Securities			Diluted Calculation
Numerator:
Net loss	$	(11,024	)	$	(291	)	$	(11,315	)
Deemed dividend related to inducement warrants		-			-			-
Net loss attributable to common stockholders	$	(11,024	)	$	(291	)	$	(11,315	)

Denominator:
Number of shares used in per common share calculations:		741,250			3,532			744,782

Net loss per common share:
Net loss	$	(14.87	)	$	(82.39	)	$	(15.19	)
Deemed dividend related to inducement warrants		-			-			-
Net loss attributable to common stockholders	$	(14.87	)	$	(82.39	)	$	(15.19	)

Recent Accounting Pronouncements

Recent Accounting Pronouncements

ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures

ASU 2024-03, Income Statement—Reporting Comprehensive Income (Topic 220): Disaggregation of Income Statement Expenses

Inventories (Details Narrative) $ in Millions	12 Months Ended
Inventories (Details Narrative) $ in Millions	Dec. 31, 2024 USD ($)
SINTX Armor Inc [Member]
Inventory [Line Items]
Impairment of inventories	$ 0.2

Equity (Details Narrative) - USD ($)							12 Months Ended
Equity (Details Narrative) - USD ($)	Oct. 03, 2025	Sep. 08, 2025	Feb. 20, 2025	Apr. 05, 2024	Mar. 26, 2024	Feb. 02, 2024	Dec. 31, 2025	Dec. 31, 2024	Feb. 25, 2025
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock, par value							$ 0.01	$ 0.01
Gross proceeds from exercise warrant							$ 206,000
Fair value of new warrants issued as part of the inducement		$ 6,700,000
Proceeds from Issuance of Private Placement			$ 5,000,000.0
Common stock shares issued			1,171,189				3,970,869	1,342,853
Proceeds from issuance of common stock							$ 4,380,000	$ 6,075,000
Proceeds from issuance of warrants								$ 3,366,000
2024 April Registered Offering [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Public offering price				$ 4.20
Number of shares issued				358,000
Proceeds from issuance of common stock				$ 1,500,000
2024 March Registered Offering [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Public offering price					$ 9.40
Number of shares issued					142,000
Proceeds from issuance of common stock					$ 1,300,000
2024 February Registered Offering [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock, par value						$ 0.01
Warrant term						5 years
Warrants exercisable, exercise price						$ 55.00
Exercise price						$ 50.00
Number of shares issued						80,000
Common units to purchase shares of common stock						17,000
Cash placement fee percentage						7.00%
Reimbursement of expenses and legal fees						$ 100,000,000
2024 February Registered Offering [Member] \| Maximum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants to purchase						3,200
2024 February Registered Offering [Member] \| Common Unit [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Sale of stock price						$ 50.00
2024 February Registered Offering [Member] \| Pre Funded Warrant Unit [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Sale of stock price						$ 49.98
2024 February Registered Offering [Member] \| Class E and F Warrants [Member] \| Nonconsolidated Investees, Other [Member] \| Minimum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beneficial ownership percentage						4.99%
2024 February Registered Offering [Member] \| Class E and F Warrants [Member] \| Nonconsolidated Investees, Other [Member] \| Maximum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beneficial ownership percentage						9.99%
2024 February Registered Offering [Member] \| Class E Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant term						5 years
2024 February Registered Offering [Member] \| Class F Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant term						18 months
2024 February Registered Offering [Member] \| Pre-Funded Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise price						$ 0.0001
2024 February Registered Offering [Member] \| Pre-funded Warrants [Member] \| Nonconsolidated Investees, Other [Member] \| Minimum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beneficial ownership percentage						4.99%
2024 February Registered Offering [Member] \| Pre-funded Warrants [Member] \| Nonconsolidated Investees, Other [Member] \| Maximum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beneficial ownership percentage						9.99%
Pre-Funded Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants to purchase			278,098
Warrants exercisable, exercise price			$ 0.0001
Exercise price			$ 3.4499
Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants to purchase			1,449,287
Warrants exercisable, exercise price			$ 3.32
Exercise price			$ 3.45
Warrant exercise description			expire five-and one-half years from issuance
Warrant [Member] \| 2024 February Registered Offering [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued						63,000
Warrants to purchase common stock						63,000
Proceeds from issuance of warrants						$ 4,000,000.0
Class E Warrants [Member] \| 2024 February Registered Offering [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants to purchase common stock						80,000
Class F Warrants [Member] \| 2024 February Registered Offering [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants to purchase common stock						80,000
2025 ATM Agreement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock, par value	$ 0.01
Offering price	$ 6,413,876
Inducement Letter [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants to purchase		1,649,147							1,099,431
Warrant term									5 years 6 months
Warrants exercisable, exercise price		$ 4.79							$ 3.32
Public offering price		$ 0.125
Gross proceeds from exercise warrant		$ 3,800,000

Equity

12 Months Ended

Dec. 31, 2025

Equity [Abstract]

Equity

8. Equity

2025 ATM Agreement

On October 3, 2025, the Company entered into an At The Market Offering Agreement (the “2025 ATM Agreement”) with H.C. Wainwright & Co., LLC, as sales agent (“Wainwright”), to sell shares of its common stock, par value $0.01 per share (the “2025 ATM Shares”) from time to time, through an “at the market offering” program under which Wainwright will act as sales agent. The sales, if any, of the 2025 ATM Shares made under the 2025 ATM Agreement will be made by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415 promulgated under the Securities Act of 1933, as amended, including, without limitation, sales made directly on or through the Nasdaq Capital Market or on any other existing trading market for the Company’s common stock. The 2025 ATM Shares will be issued pursuant to the Company’s shelf registration statement on Form S-3 (File No. 333-274951) initially filed by the Company with the SEC on October 12, 2023, and declared effective by the SEC on November 27, 2023, and related prospectus supplements to be prepared and filed pursuant to Rule 424(b) from time to time in connection with the offer and sale of the Shares. A prospectus supplement, dated October 3, 2025, covering the offer and sale of the 2025 ATM Shares having an aggregate offering price of $6,413,876 was filed with the SEC.

2025 Warrant Inducement

On September 8, 2025, the Company entered into an inducement agreement (the “Inducement Letter”) with certain holders of certain of the Company’s existing warrants to purchase up to an aggregate of 1,099,431 shares of the Company’s common stock originally issued on February 25, 2025, with a five and one-half (5.5) years term at an exercise price of $3.32 per share.

Pursuant to the Inducement Letter, the warrant holders agreed to exercise for cash the existing warrants to purchase an aggregate of 1,099,431 shares of the Company’s common stock at an exercise price of $3.32 per share in consideration of the Company’s agreement to issue new common stock purchase warrants to purchase up to an aggregate of 1,649,147 shares of the Company’s common stock at an exercise price of $4.79 per share. In addition, the warrant holders agreed to pay $0.125 per new warrant as consideration for the issuance of the new warrants. The Company received aggregate gross proceeds of approximately $3.8 million from the exercise of the existing warrants by the warrant holder, before deducting placement agent fees and other offering expenses payable by the Company.

The Company estimated the fair value of each warrant on the issuance date using the Black-Scholes-Merton valuation model. The aggregate fair value of the new warrants issued as part of the inducement was $6.7 million, which is presented as a deemed dividend on the consolidated statements of operations and the consolidated statements of stockholders’ equity.

2025 Capital Raise and Registration of Shares

On February 20, 2025, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) under which it sold securities to certain institutional and accredited investors for aggregate gross proceeds of $5.0 million, before deducting fees to the placement agent and other expenses payable by the Company in connection with the private placement. As part of the Private Placement, the Company issued (i) 1,171,189 shares of the Company’s common stock, (ii) pre-funded warrants to purchase 278,098 shares of common stock (the “Pre-Funded Warrants”) with an exercise price of $0.0001 per share, and (iii) warrants to purchase 1,449,287 shares of common stock (the “Common Warrants”) with an exercise price of $3.32 per share. The purchase price per share of common stock and the associated Common Warrant was $3.45 and the purchase price per Pre-Funded Warrant and associated Common Warrant was $3.4499. The Common Warrants are exercisable immediately and expire five-and one-half years from issuance. The Pre-Funded Warrants are exercisable immediately and terminate when exercised in full. The Company filed a Registration Statement on Form S-3 registering the resale of the above-mentioned Securities, which was declared effective by the SEC on March 27, 2025.

2024 April Registered Offering

On April 5, 2024, the Company closed on a public offering 358,000 shares of the Company’s common stock, (the “Offering”). Each Share was sold at a public offering price of $4.20. The aggregate proceeds to the Company from the Offering were approximately $1.5 million before deducting placement agent fees and other estimated offering expenses payable by the Company.

2024 March Registered Offering

On March 26, 2024, the Company closed on a public offering of 142,000 shares of the Company’s common stock, (the “Offering”). Each Share was sold at a public offering price of $9.40. The aggregate proceeds to the Company from the Offering were approximately $1.3 million before deducting placement agent fees and other estimated offering expenses payable by the Company.

2024 February Registered Offering

On February 2, 2024, the “Company closed on the public offering of 80,000 units consisting of (a)(i) 17,000 units (the “Common Units”) to purchase shares (the “Unit Shares”) of the Company’s Common Stock, par value $0.01 per share (the “Common Stock”) and (ii) 63,000 units (the “Pre-Funded Warrant Units” and together with the Common Units, the “Units”) to purchase pre-funded warrants (the “Pre-Funded Warrants and each share of Common Stock underlying a Pre-Funded Warrant, a “Pre-Funded Warrant Share”) to purchase up to 63,000 shares of Common Stock, (b) accompanying Class E warrants to purchase 80,000 shares of the Company’s Common Stock (the “Class E Warrants”), and (c) accompanying Class F warrants to purchase 80,000 shares of the Company’s Common Stock (the “Class F Warrants”). The aggregate proceeds to the Company from the Offering were approximately $4.0 million before deducting placement agent fees and other offering expenses payable by the Company. The offering was made pursuant to a securities purchase agreement (the “Purchase Agreement”) with certain investors (the “Purchasers”), and a placement agency agreement dated as of January 31, 2024 (the “PAA”) with Maxim Group LLC (the “Placement Agent”). Each Common Unit was sold at a public offering price of $50.00 and each Pre-Funded Warrant Unit was sold at a public offering price of $49.98. The Class E Warrants and the Class F Warrants are immediately exercisable (subject to the beneficial ownership cap at 4.99% or 9.99%) for one share of the Company’s Common Stock at an exercise price of $50.00 per share. The Class E Warrants will expire five years from the date of issuance, and the Class F Warrants will expire 18 months from the date of issuance. Each Pre-Funded Warrant is exercisable for one share of the Company’s Common Stock at an exercise price of $0.0001 per share. The Pre-Funded Warrants are immediately exercisable (subject to the beneficial ownership cap at 4.99% or 9.99%) and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The Company engaged Maxim Group LLC as the Company’s sole placement agent for the Offering pursuant to the PAA. Pursuant to the PAA, the Company agreed to pay the Placement Agent a cash placement fee equal to 7.0% of the gross proceeds of the Offering, plus reimbursement of certain expenses and legal fees up to $100,000. The Company also agreed to issue up to 3,200 Common Stock purchase warrants to the Placement Agent (the “Placement Agent Warrants”). The Placement Agent Warrants are exercisable at an exercise price of $55.00. The Placement Agent Warrants will be exercisable beginning July 31, 2024, and will expire five years after the commencement of sales in the offering.

- Definition

The entire disclosure for equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478448/946-505-50-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480237/815-40-50-6

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/505/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-16

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

+ Details

Schedule of Financial Liabilities Measured at Fair Value on Recurring Basis by Level Within Fair Value Hierarchy (Details) - Fair Value, Recurring [Member] - Common Stock Warrants [Member] - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Derivative liability	$ 827	$ 208
Fair Value, Inputs, Level 1 [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Derivative liability
Fair Value, Inputs, Level 2 [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Derivative liability
Fair Value, Inputs, Level 3 [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Derivative liability	$ 827	$ 208

- Definition

Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.

+ References + Details

401(k) Plan (Details Narrative) - USD ($) $ in Millions	12 Months Ended
401(k) Plan (Details Narrative) - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024
Retirement Benefits [Abstract]
Retirement contributions	$ 0.1	$ 0.1

Schedule of Significant Components of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Deferred tax assets:
Net operating loss carryforwards	$ 59,358	$ 57,763
Stock-based compensation	3,690	3,192
Federal R&D credit	2,120	2,222
Impairment	1,146	1,148
Accrued expenses		53
Capitalized research expenses	2,217	3,145
Intangibles	186	237
Right of use asset/liabilities	32	32
Depreciation	243
Other	1	15
Total deferred tax assets	68,993	67,807
Deferred tax liabilities:
Depreciation		(431)
Total deferred tax liabilities		(431)
Less valuation allowance	(68,993)	(67,376)
Net deferred tax liability

Schedule of Income Taxes Paid (Details) - USD ($)	12 Months Ended
Schedule of Income Taxes Paid (Details) - USD ($)	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Income Tax Disclosure [Abstract]
Federal
State and local
Foreign
Total income taxes paid (net of refunds received)		$ 0	$ 0

Schedule of Unrecognized Stock-based Compensation (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2025 USD ($)
Share-Based Payment Arrangement, Option [Member]
Subsidiary, Sale of Stock [Line Items]
Unrecognized stock-based compensation
Weighted average remaining of recognition	0 years
Employee Stock Grants [Member]
Subsidiary, Sale of Stock [Line Items]
Unrecognized stock-based compensation	$ 1,497
Weighted average remaining of recognition	10 months 24 days

Debt

12 Months Ended

Dec. 31, 2025

Debt Disclosure [Abstract]

Debt

7. Debt

Insurance Premium Finance Arrangements

In June 2024, in connection with securing commercial liability insurance, the Company entered into a Premium Finance Arrangement to extend the premium payment out for a period of 10 months. The Company paid a total of $26,000 up front toward the insurance premium and financed approximately $117,000. The Company made 10 equal payments under the terms of the Premium Finance Agreement. The Premium Finance Agreement bears interest at an annual percentage rate of 8.75%. The loan was paid in full during the first quarter of 2025.

In March 2025, in connection with securing Director and Officer professional liability insurance, the Company entered into a Premium Finance Arrangement to extend the premium payment out for a period of 10 months. The Company paid a total of $26,000 up front toward the insurance premium and financed approximately $145,000. The Company will make 10 equal payments under the terms of the Premium Finance Agreement. The Premium Finance Agreement bears interest at an annual percentage rate of 7.45%. The loan was paid in full during 2025.

In May 2025, in connection with securing general liability insurance, the Company entered into a Premium Finance Arrangement to extend the premium payment out for a period of 5 months. The Company paid a total of $14,000 up front toward the insurance premium and financed approximately $21,000. The Company will make 3 equal payments under the terms of the Premium Finance Agreement. The Premium Finance Agreement bears interest at an annual percentage rate of 11.15%. The outstanding balance totaled $7,000 as of December 31, 2025.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 470
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/470/tableOfContent

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482925/835-30-45-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

+ Details

Cover - USD ($)	12 Months Ended
Cover - USD ($)	Dec. 31, 2025	Mar. 13, 2026	Jun. 30, 2025
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2025
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2025
Current Fiscal Year End Date	--12-31
Entity File Number	001-33624
Entity Registrant Name	SINTX Technologies, Inc.
Entity Central Index Key	0001269026
Entity Tax Identification Number	84-1375299
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	1885 West 2100 South
Entity Address, City or Town	Salt Lake City
Entity Address, State or Province	UT
Entity Address, Postal Zip Code	84119
City Area Code	(801)
Local Phone Number	839-3500
Title of 12(b) Security	Common Stock, $0.01 par value
Trading Symbol	SINT
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 7,651,741
Entity Common Stock, Shares Outstanding		4,121,727
Documents Incorporated By Reference	None
ICFR Auditor Attestation Flag	false
Document Financial Statement Error Correction [Flag]	false
Entity Listing, Par Value Per Share	$ 0.01
Auditor Opinion [Text Block]	We have audited the accompanying consolidated balance sheets of SINTX Technologies, Inc. and subsidiaries (the “Company”) as of December 31, 2025 and 2024, the related consolidated statements of operations, stockholders’ equity, and cash flows for each of the years in the two-year period ended December 31, 2025, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the years in the two-year period ended December 31, 2025, in conformity with accounting principles generally accepted in the United States of America.
Auditor Name	TANNER LLP
Auditor Firm ID	270
Auditor Location	Lehi, Utah

Debt (Details Narrative) - Insurance Premium Finance Arrangements [Member] - USD ($)	1 Months Ended			12 Months Ended
	May 31, 2025	Mar. 31, 2025	Jun. 30, 2024	Dec. 31, 2025
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Up front insurance premium			$ 26,000
Financed insurance premium			$ 117,000
Annual interest rate			8.75%
Director and Officer Professional Liability Insurance [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Up front insurance premium		$ 26,000
Financed insurance premium		$ 145,000
Annual interest rate		7.45%		11.15%
Payment of insurance premium	$ 14,000
Payments to financed total	$ 21,000
Outstanding balance				$ 7,000

Income Taxes

12 Months Ended

Dec. 31, 2025

Income Tax Disclosure [Abstract]

Income Taxes

10. Income Taxes

Taxes based on income were as follows:

Schedule of Tax Based on Income

		2025		2024
		December 31,
		2025		2024

Current:	$	-	$	-
U.S. federal tax		-		-
State taxes	$	-	$	-

Deferred:
U.S. federal tax	$	-	$	-
State tax		-		-
	$	-	$	-

Provision for income taxes	$	-	$	-

	2025			2024
	December 31,
	2025			2024
Deferred tax assets:
Net operating loss carryforwards	$	59,358		$	57,763
Stock-based compensation		3,690			3,192
Federal R&D credit		2,120			2,222
Impairment		1,146			1,148
Accrued expenses		-			53
Capitalized research expenses		2,217			3,145
Intangibles		186			237
Right of use asset/liabilities		32			32
Depreciation		243			-
Other		1			15
Total deferred tax assets		68,993			67,807
Deferred tax liabilities:
Depreciation		-			(431	)

Total deferred tax liabilities		-			(431	)
Less valuation allowance		(68,993	)		(67,376	)
Net deferred tax liability	$	-		$	-

We assess available positive and negative evidence to estimate if sufficient future taxable income is expected to be generated to use existing deferred tax assets. On the basis of our assessment, we record valuation allowances with respect to the portion of the deferred tax asset that is not more-likely-than-not to be realized. Our assessment of the future realizability of our deferred tax assets relies on our forecasted earnings in certain jurisdictions determined by the manner in which we operate our business and the relevant carryforward period. As a result of all available evidence, the Company believes that it is more likely than not that its net deferred tax assets will not be realized and has established a valuation allowance of $69.0 million and $67.4 million, respectively, against its net deferred tax assets as of December 31, 2025 and December 31, 2024.

U.S. federal net operating loss carryforwards at December 31, 2025 and December 31, 2024 were $237.9 million and 231.5 million, respectively. U.S. federal tax credit carryforwards at December 31, 2025 and December 31, 2024 totaled $2.1 million and $2.2 million, respectively. If unused, net operating losses and tax credit carryforwards will expire as follows:

(in millions)	Operating Losses		Tax Credits
Year of expiry:
2026	$	5.1	$	0.2
2027		11.5		0.2
2028		15.3		0.5
2029		15.9		0.3
2030-2037		114.8		0.9
Indefinite life / no expiry		75.3		0.0
Total	$	237.9	$	2.1

State net operating loss carryforwards totaled approximately $237.9 million at December 31, 2025. State net operating losses in certain jurisdictions begin to expire in 2033 and continue through 2045, while net operating losses in other jurisdictions may be carried forward indefinitely.

The principal items accounting for the difference between taxes computed at the U.S. federal statutory rate and taxes recorded were as follows (in thousands) after the adoption of ASU 2023-09:

	2025			2024
	Year Ended December 31, 2025
	Amount			Percent

U.S. federal statutory tax rate	$	(2,176	)		(21.00	)%
State and local income taxes, net of federal income tax effect		-			0.00	%
Foreign tax effects		-			0.00	%
Effect of changes in tax laws or rates enacted in the current period		-			0.00	%
Effect of cross-border tax laws		-			0.00	%
Tax credits:
Research and development tax credits		102			0.99	%
Changes in valuation allowances		1,617			15.60	%
Nontaxable or nondeductible items:
Change in value – warrants		26			0.25	%
Other		6			0.06	%
Changes in unrecognized tax benefits		-			0.00	%
Other adjustments		425			4.10	%
Effective tax rate	$	-			-

	Year Ended December 31, 2024

Pre-tax book income tax at statutory rate	$	(2,315	)
State taxes, net of federal benefit		(482	)
Return to provision		-
Equity related expenses		(614	)
Deferred adjustments		-
Expiration of R&D credits		-
Change in valuation allowance		3,409
Other		2
Total income tax expense	$	-

The following is a reconciliation of the expected statutory federal income tax rate to the actual effective tax rate (in thousands):

	2024
	Year Ended December 31, 2024
Federal statutory rate		(21.0	)%
State taxes, net of federal benefit		(4.3	)%
Return to provision		0.0	%
Equity related expenses		(5.6	)%
Deferred adjustments		0.0	%
Expiration of R&D credits		0.0	%
Change in valuation allowance		30.9	%
Total income tax expense		0.0	%

Our 2025 provision for income taxes included i) $0.02 million of tax charge for equity related expenses; ii ) $0.42 million of tax charge for certain deferred tax adjustments; iii) $1.62 million of tax charge from changes in valuation allowances; iv) $.10 million tax charge for expiration of R&D credits; and v) $0.006 million of tax charge related to other permanent differences.

Our 2024 provision for income taxes included i) $0.48 million state tax benefit net of federal affect; ii) $0.61 million of tax benefit for equity related expenses; iii) $3.41 million of tax charge from valuation allowances due to the uncertainty of the realization of certain deferred tax assets; and iv) $0.002 million of tax charge related to other permanent differences.

Income/(loss) before taxes from our U.S. operations was follows:

Schedule of Income Loss Before Taxes

	2025			2024
U.S.	$	(10,364	)	$	(11,024	)
Foreign		-			-
Income before taxes	$	(10,364	)	$	(11,024	)

Our effective tax rate was 0.00% and 0.00% for fiscal years 2025 and 2024, respectively.

The Company files income tax returns in the U.S. federal and certain state jurisdictions. During the periods ended December 31, 2025 and December 31, 2024, the Company has not recorded a liability for uncertain income tax positions or any related interest or penalties. As such, our unrecognized tax benefits for 2025 and 2024 totaled $0.00 million and $0.00 million, respectively. With limited exceptions, we are no longer subject to income tax examinations by tax authorities for years prior to 2021.

The amount of income taxes paid (net of refunds received) were as follows (in thousands):

	Year Ended December 31, 2025
Federal	$	-
State and local		-
Foreign		-
Total income taxes paid (net of refunds received)	$	-

Amounts represent taxes paid during 2025 based on the company’s tax provision. The 2025 income tax returns have not been filed. For the years ended December 31, 2024 and 2023, gross income taxes paid (in thousands) were $0 and $0, respectively.

- Definition

The entire disclosure for income tax.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 740
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477617/942-740-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 740
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478822/944-740-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477891/740-270-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-13

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/740/tableOfContent

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-14

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-21

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-17

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482603/740-30-50-2

+ Details

Schedule of Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]
Options outstanding at beginning	35	60
Weighted average exercisable price	$ 18,872	$ 21,954
Weighted average remaining contractual terms (years), outstanding at ending	9 years 4 months 24 days	5 years 6 months	6 years 10 months 24 days
Intrinsic value, outstanding at beginning of period
Options, granted	170,000
Weighted average exercise price, granted	$ 3.65
Weighted average remaining contractual terms (years), outstanding at beginning	9 years 4 months 24 days
Options, exercised
Weighted average exercise price, exercised
Options, forfeited		24,000
Weighted average exercise price, forfeited		$ 3,861,275,000
Options, expired	(9)	(1)
Weighted average exercise price, expired	$ 17,540	$ 891,768,343
Options, outstanding at end	170,026	35	60
Weighted average exercise price, outstanding at end of period	$ 6.65	$ 18,872	$ 21,954
Intrinsic value, outstanding at end of period	$ 77,600
Options, exercisable at end	170,026	35
Weighted average exercise price, exercisable at end of period	$ 6.65	$ 24,292
Weighted average remaining contractual terms (years), exercisable	9 years 4 months 24 days	6 years 1 month 6 days
Intrinsic value, exercisable at end of period	$ 77,600
Vested and expected to vest at end	170,026	10
Weighted average exercise price, vested and expected to vest at end	$ 6.65	$ 38,168
Weighted average remaining contractual terms (years), vested and expected to vest	9 years 4 months 24 days	5 years 6 months
Intrinsic value, vested and expected to vest end of period	$ 77,600
Options, forfeited		(24,000)

Related Party Transactions

12 Months Ended

Dec. 31, 2025

Related Party Transactions

14. Related Party Transactions

During the year ended December 31, 2025, the Company entered into a Research Collaboration Agreement (“Research Agreement”) with a company that is majority owned by a shareholder of the Company. The Company paid $500,000 to fund the Research Agreement. As of December 31, 2025, there was no remaining balance.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-5

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-6

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(g)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(c))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(e))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/850/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-6

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

+ Details

Schedule of Intangible Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Trademarks and other patent related intangible assets	$ 195	$ 50
Less: accumulated amortization	(53)	(34)
Intangible assets,net	$ 142	$ 16

Schedule of Fair Value Measurement Hierarchy of Derivative Liability (Details) - Common Stock Warrants [Member] - Fair Value, Inputs, Level 3 [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Beginning balance	$ 208	$ 304
Issuance of derivatives	495	3,366
Exercise of warrants		(1)
Change in fair value	(124)	(3,475)
Other		14
Change in fair value	124	3,475
Ending balance	$ 827	$ 208

Commitment and Contingencies

12 Months Ended

Dec. 31, 2025

Commitments and Contingencies Disclosure [Abstract]

Commitment and Contingencies

11. Commitment and Contingencies

The Company has executed agreements with certain executive officers of the Company which, upon the occurrence of certain events related to a change in control, call for payments to the executives up to three times their annual salary and accelerated vesting of previously granted stock options.

From time to time, the Company is subject to various claims and legal proceedings covering matters that arise in the ordinary course of its business activities. Management believes any liability that may ultimately result from the resolution of these matters will not have a material adverse effect on the Company’s consolidated financial position, operating results or cash flows.

Stock-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2025

Share-Based Payment Arrangement [Abstract]

Schedule of Stock Option Activity

A summary of the Company’s outstanding stock option activity for the years ended December 31, 2025 and 2024 is as follows:

Schedule of Stock Option Activity

				December 31, 2025
				Weighted- Average Exercise		Weighted- Average Remaining Contractual Life		Intrinsic
	Options			Price		(Years)		Value
As of December 31, 2024		35		$	18,872		5.5		-
Granted		170,000			3.65		9.4		-
Exercised		-			-		-		-
Forfeited		-			-		-		-
Expired		(9	)		17,540		-		-
As of December 31, 2025		170,026		$	6.65		9.4	$	77,600
Exercisable at December 31, 2025		170,026		$	6.65		9.4	$	77,600
Vested and expected to vest at December 31, 2025		170,026		$	6.65		9.4	$	77,600

				December 31, 2024
				Weighted- Average Exercise		Weighted- Average Remaining Contractual Life		Intrinsic
	Options			Price		(Years)		Value
As of December 31, 2023		60		$	21,954		6.9		-
Granted		-			-		-		-
Exercised		-			-		-		-
Forfeited		(24	)		3,861,275		-		-
Expired		(1	)		891,768,343		-		-
As of December 31, 2024		35		$	18,872		5.5	$	-
Exercisable at December 31, 2024		35		$	24,292		6.1	$	-
Vested and expected to vest at December 31, 2024		10		$	38,168		5.5	$	-

Schedule of Unrecognized Stock-based Compensation

Unrecognized stock-based compensation as of December 31, 2025 is as follows (in thousands):

Unrecognized

Stock-Based

Compensation

Weighted

Average

Remaining
of

Recognition
(in years)

Stock options

0.0

Stock grants

1,497

0.9

Property and Equipment

12 Months Ended

Dec. 31, 2025

Property, Plant and Equipment [Abstract]

Property and Equipment

3. Property and Equipment

The following is a summary of the components of property and equipment (in thousands):

	2025			2024
	As of December 31,
	2025			2024
Manufacturing and lab equipment	$	1,783		$	2,220
Leasehold improvements		989			968
Software and computer equipment		674			664
Furniture and equipment		82			118
Property and equipment, gross		3,528			3,970
Less: accumulated depreciation		(3,052	)		(3,048	)
Property and equipment, net	$	476		$	922

Depreciation expense for 2025 and 2024 was $0.3 million and $0.8 million, respectively. Impairment of property and equipment of $3.7 million was recorded during 2024 related to Armor exit costs, and is included in Armor exit costs in the statement of operations.

Schedule of Tax Based on Income (Details) - USD ($)	12 Months Ended
Schedule of Tax Based on Income (Details) - USD ($)	Dec. 31, 2025	Dec. 31, 2024
Income Tax Disclosure [Abstract]
U.S. federal tax
State taxes
U.S. federal tax
State tax
Provision for income taxes

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-4

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-21

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.7)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-10

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Subparagraph (a)
-SubTopic 20
-Topic 740
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482659/740-20-45-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-SubTopic 10
-Topic 235
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

+ Details

Schedule of Operating Losses and Tax Credit Carryforwards (Details) - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024
Operating Loss Carryforwards [Line Items]
Total	$ 237.9	$ 231.5
Total	2.1	$ 2.2
Tax Year 2026 [Member]
Operating Loss Carryforwards [Line Items]
Total	5.1
Total	0.2
Tax Year 2027 [Member]
Operating Loss Carryforwards [Line Items]
Total	11.5
Total	0.2
Tax Year 2028 [Member]
Operating Loss Carryforwards [Line Items]
Total	15.3
Total	0.5
Tax Year 2029 [Member]
Operating Loss Carryforwards [Line Items]
Total	15.9
Total	0.3
Tax Year 2030 To 2037 [Member]
Operating Loss Carryforwards [Line Items]
Total	114.8
Total	0.9
Tax Year Indefinite Life [Member]
Operating Loss Carryforwards [Line Items]
Total	75.3
Total	$ 0.0

Schedule of Reconciliation Statutory Federal Income Tax Provision to Actual Income Tax Benefit (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Income Tax Disclosure [Abstract]
Pre-tax book income tax at statutory rate	$ (2,176)	$ (2,315)
Federal statutory rate	(21.00%)	(21.00%)
State taxes, net of federal benefit		$ (482)
State taxes, net of federal benefit	0.00%	(4.30%)
Foreign tax effects
Foreign tax effects	0.00%
Effect of changes in tax laws or rates enacted in the current period
Effect of changes in tax laws or rates enacted	0.00%
Effect of cross-border tax laws
Effect of cross-border tax laws	0.00%
Research and development tax credits	$ 102
Research and development tax credits	0.99%
Change in valuation allowance	$ 1,617	$ 3,409
Change in valuation allowance	15.60%	30.90%
Change in value – warrants	$ 26
Change in value warrants	0.25%
Other	$ 6	$ 2
Other	0.06%
Changes in unrecognized tax benefits
Change in unrecognized tax benefits	0.00%
Other adjustments	$ 425
Other adjustments	4.10%
Total income tax expense
Total income tax expense	(0.00%)	0.00%
Return to provision
Equity related expenses		(614)
Deferred adjustments
Expiration of R&D credits
Return to provision		0.00%
Equity related expenses		(5.60%)
Deferred adjustments		0.00%
Expiration of R&D credits		0.00%

Consolidated Balance Sheets - USD ($)	Dec. 31, 2025	Dec. 31, 2024
Current assets:
Cash and cash equivalents	$ 4,140,000	$ 3,598,000
Account and other receivables, net of allowance totaling $2.4 and $61.0 respectively	178,000	196,000
Prepaid expenses and other current assets	507,000	225,000
Inventories	825,000	502,000
Total current assets	5,650,000	4,521,000
Inventories, net	219,000	465,000
Property and equipment, net	476,000	922,000
Intangible assets, net	142,000	16,000
Goodwill	302,000
Operating lease right of use asset	2,458,000	3,159,000
Other long-term assets	259,000	330,000
Total assets	9,506,000	9,413,000
Current liabilities:
Accounts payable	382,000	299,000
Accrued liabilities	422,000	986,000
Debt	7,000	32,000
Derivative liabilities	827,000	208,000
Current portion of operating lease liability	398,000	456,000
Other current liabilities	1,697,000	1,000
Total current liabilities	3,733,000	1,982,000
Operating lease liability, net of current portion	2,844,000	3,537,000
Total liabilities	6,577,000	5,519,000
Commitments and contingencies
Stockholders’ equity:
Treasury stock, 50,424 shares as of December 31, 2025	(133,000)
Common stock, $0.01 par value, 250,000,000 shares authorized; 3,970,869 and 1,342,853 shares issued and outstanding as of December 31, 2025 and 2024, respectively.	40,000	13,000
Additional paid-in capital	295,124,000	285,619,000
Accumulated deficit	(292,102,000)	(281,738,000)
Total stockholders’ equity	2,929,000	3,894,000
Total liabilities and stockholders’ equity	9,506,000	9,413,000
Series B Convertible Preferred Stock [Member]
Stockholders’ equity:
Convertible preferred stock, value
Series C Convertible Preferred Stock [Member]
Stockholders’ equity:
Convertible preferred stock, value
Series D Convertible Preferred Stock [Member]
Stockholders’ equity:
Convertible preferred stock, value

Income Taxes (Details Narrative) - USD ($)	12 Months Ended
Income Taxes (Details Narrative) - USD ($)	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Effective Income Tax Rate Reconciliation [Line Items]
Valuation allowance	$ 68,993,000	$ 67,376,000
Net operating loss carryforwards	237,900,000	231,500,000
U.S. federal tax credit carryforwards	$ 2,100,000	$ 2,200,000
Provision for income taxes description	provision for income taxes included i) $0.02 million of tax charge for equity related expenses; ii ) $0.42 million of tax charge for certain deferred tax adjustments; iii) $1.62 million of tax charge from changes in valuation allowances; iv) $.10 million tax charge for expiration of R&D credits; and v) $0.006 million of tax charge related to other permanent differences.	provision for income taxes included i) $0.48 million state tax benefit net of federal affect; ii) $0.61 million of tax benefit for equity related expenses; iii) $3.41 million of tax charge from valuation allowances due to the uncertainty of the realization of certain deferred tax assets; and iv) $0.002 million of tax charge related to other permanent differences.
Effective tax rate	(0.00%)	0.00%
Unrecognized tax benefits	$ 0.00	$ 0.00
Income taxes paid net		$ 0	$ 0
State and Local Jurisdiction [Member]
Effective Income Tax Rate Reconciliation [Line Items]
Net operating loss carryforwards	$ 237,900,000

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Total revenue	$ 1,018	$ 2,887
Cost of revenue	557	811
Gross profit	461	2,076
Operating expenses:
Research and development	4,587	5,201
General and administrative	6,197	3,997
Sales and marketing	242	614
Armor exit costs		4,602
Reduction in force		407
Grant and contract expenses	156	1,302
Total operating expenses	11,182	16,123
Loss from operations	(10,721)	(14,047)
Other income (expenses):
Interest expense	(52)	(29)
Interest income	175	107
Gain (loss) on the disposal of assets	327	(19)
Change in fair value of derivative liabilities	(124)	3,475
Offering costs of derivative liabilities		(550)
Other income (expense)	31	39
Total other income (expense), net	357	3,023
Net loss before income taxes	(10,364)	(11,024)
Provision for income taxes
Net loss	(10,364)	(11,024)
Deemed dividend related to warrant inducement	(6,719)
Net loss attributable to common stockholders	$ (17,083)	$ (11,024)
Net loss per share – basic and diluted
Basic – net loss	$ (3.74)	$ (14.87)
Basic – deemed dividend related to warrant inducement	(2.42)
Basic – attributable to common stockholders	(6.16)	(14.87)
Diluted – net loss	(3.74)	(15.19)
Diluted - deemed dividend related to warrant inducement	(2.42)
Diluted – attributable to common stockholders	$ (6.16)	$ (15.19)
Weighted average common shares outstanding:
Basic	2,773,518	741,250
Diluted	2,773,518	744,782
Product [Member]
Total revenue	$ 729	$ 1,246
Grant and Contract [Member]
Total revenue	$ 289	$ 1,641

Accrued Liabilities

12 Months Ended

Dec. 31, 2025

Payables and Accruals [Abstract]

Accrued Liabilities

6. Accrued Liabilities

Accrued liabilities consisted of the following (in thousands):

Schedule of Accrued Liabilities

	2025		2024
	As of December 31,
	2025		2024
Payroll and related expenses	$	120	$	400
Accrued payables		50		178
Other		252		408
Accrued liabilities	$	422	$	986

Other current liabilities consisted of deposits for stock issuance of $1.7 million. The stock issuance is related to the 2025 Warrant Inducement (see Note 8), and the stock is held in abeyance, as of December 31, 2025.

Intangible Assets

12 Months Ended

Dec. 31, 2025

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets

4. Intangible Assets

Intangible assets consisted of the following (in thousands):

Schedule of Intangible Assets

	2025			2024
	As of December 31,
	2025			2024
Trademarks and other patent related intangible assets	$	195		$	50
Less: accumulated amortization		(53	)		(34	)
Intangible assets,net	$	142		$	16

Amortization expense for 2025 and 2024 was $19 thousand and $5 thousand, respectively.

Leases

12 Months Ended

Dec. 31, 2025

Leases

Leases

13. Leases

The Company has entered into multiple operating leases from which it conducts its business.

SINTX

The Company leases 30,764 square feet of office, warehouse and manufacturing space under a single operating lease. This lease expires in October 2031. The lease has one five-year extension option.

SINTX Armor

The Company, on behalf of SINTX Armor, leases approximately 10,936 square feet of office and manufacturing space from which SINTX Armor conducted its operations. This lease expires in October 2031. Impairment of operating lease right-of-use assets of $0.7 million was recorded during 2024 related to Armor exit costs. In October 2025, the Company entered into a sublease agreement (the “Sublease”) with Hayes Performance Systems, Inc., a Delaware corporation (“Hayes”), pursuant to which the Company agreed to sublease to Hayes all of the premises the Company currently leases under its Industrial Lease Agreement dated August 19, 2021 with SLS Industrial Portfolio Owner SLCP, LLC (the “Prime Lease”). The Sublease term commenced on November 1, 2025, and expires on October 31, 2031, unless earlier terminated in accordance with the Sublease or upon termination of the Prime Lease. Under the Sublease, Hayes will pay the Company base rent ranging from approximately $9,700 per month during the first year of the Sublease to approximately $11,300 per month during the final year of the term, plus its proportionate share of operating expenses and taxes, currently estimated at $0.25 per rentable square foot per month. The Sublease provides for a three-month rent deferral totaling approximately $29,200, which will be repaid in six equal monthly installments beginning February 1, 2026. The Sublease is structured as a triple-net arrangement under which Hayes will be responsible for substantially all costs associated with the Subleased Premises, including utilities, maintenance, and insurance.

TA&T

In connection with the disposition of TA&T, the lease facilities, including right of use assets and lease liabilities, were transferred to Tethon (see Note 1).

Leases with an initial term of 12 months or less are not recorded on the balance sheet. Lease expense is recognized on a straight-line basis over the term of the lease. The Company accounts for lease components separately from the non-lease components. The depreciable life of the assets and leasehold improvements are limited by the expected lease term.

As of December 31, 2025, the operating lease right-of-use assets totaled approximately $2.5 million, and the operating lease liability totaled approximately $3.2 million. Amortization of right-of-use asset during the year ended December 31, 2025, totaled approximately $0.3 million. As of December 31, 2025, the weighted-average discount rate for the Company’s operating lease was 8.8%.

Operating lease future minimum payments together with the present values as of December 31, 2025, are summarized as follows:

Years Ending December 31,	Amount
2026	$	668
2027		688
2028		709
2029		730
2030		752
Thereafter		643
Total future minimum lease payments		4,190
Less amounts representing interests		(948	)
Present value of lease liability		3,242

Current portion of operating lease liability		398
Long-term portion operating lease liability	$	2,844

Leases (Details Narrative)	1 Months Ended	12 Months Ended
Leases (Details Narrative)	Oct. 31, 2025 USD ($) ft²	Dec. 31, 2025 USD ($) ft²	Dec. 31, 2024 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Area of land \| ft²		30,764
Lease expires		This lease expires in October 2031
Lease term extend		The lease has one five-year extension option
Sublease	$ 29,200
Operating lease right-of-use assets		$ 2,458,000	$ 3,159,000
Operating lease liability		3,242,000
Amortization of right-of-use asset		$ 300,000
Operating lease, weighted average discount rate, percent		8.80%
Minimum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Sublease	9,700
Maximum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Sublease	$ 11,300
Industrial Lease Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Area of land \| ft²	0.25	10,936
Armor Facility [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Lease expires		This lease expires in October 2031
Operating Lease, Impairment Loss			$ 700,000
Sublease	$ 1,000,000.0

Schedule of Components of Inventory (Details) - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Inventory Disclosure [Abstract]
Raw materials	$ 402	$ 629
WIP	296	182
Finished goods	346	156
Inventory net	$ 1,044	$ 967

Schedule of Major Classes of Assets and Liabilities of TA & T at the Date of Sale (Details) - USD ($) $ in Thousands	Dec. 31, 2025	Feb. 19, 2025
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash and cash equivalents	$ 750	$ 4
Inventories		8
Accounts receivable		91
Right of use asset		376
Property and equipment, net		248
Other assets		16
Total assets sold	$ 895	743
Accounts payable		(26)
Accrued expenses		(275)
Operating lease liability		(384)
Other liabilities		(34)
Total liabilities assumed		(719)
Net assets sold		$ 24

Schedule of Operating Lease Future Minimum Payments (Details) - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Leases
2026	$ 668
2027	688
2028	709
2029	730
2030	752
Thereafter	643
Total future minimum lease payments	4,190
Less amounts representing interests	(948)
Present value of lease liability	3,242
Current portion of operating lease liability	398	$ 456
Long-term portion operating lease liability	$ 2,844	$ 3,537

Inventories

12 Months Ended

Dec. 31, 2025

Inventory Disclosure [Abstract]

Inventories

2. Inventories

The components of inventory were as follows (in thousands):

Schedule of Components of Inventory

	2025		2024
	As of December 31,
	2025		2024
Raw materials	$	402	$	629
WIP		296		182
Finished goods		346		156
Inventory net	$	1,044	$	967

Impairment of Armor inventories of $0.2 million was recorded during 2024 related to Armor exit costs, and is included in Armor exit costs in the statement of operations.

Pay vs Performance Disclosure - USD ($) $ in Thousands	12 Months Ended
Pay vs Performance Disclosure - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Pay vs Performance Disclosure [Table]
Net Income (Loss)	$ (10,364)	$ (11,024)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-10

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-4

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-21

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(k)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3A
-Subparagraph (24)(d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 9
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-9

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 17
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480336/718-10-65-17

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479105/946-220-45-7

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 38: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 39: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 40: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 41: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 42: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 43: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 44: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7

Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 46: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A

Reference 47: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B

Reference 48: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (f)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481538/470-20-65-4

Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

+ Details

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Cash flow from operating activities
Net loss	$ (10,364)	$ (11,024)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	319	842
Amortization of right of use asset	324	537
Amortization of intangible assets	19	5
Loss on disposal of subsidiary	25
Impairment of Armor	64	4,602
Stock based compensation – Employee	1,390	82
Stock based compensation – Non-employee	606
Change in fair value of derivative liabilities	124	(3,475)
Loss (gain) on disposal of equipment	(352)	18
Bad debt expense (recoveries)	(3)	(1)
Changes in operating assets and liabilities:
Account and other receivables	(69)	490
Prepaid expenses and other assets	(47)	482
Inventories	(85)	72
Accounts payable and accrued liabilities	(200)	(756)
Other liabilities	45	(2)
Payments on operating lease liability	(367)	(514)
Net cash used in operating activities	(8,571)	(8,642)
Cash flows from investing activities
Purchase of property and equipment	(185)	(690)
Disposal of property and equipment, net of cash received	(4)
Proceeds from the sale of property and equipment	352	20
Proceeds from acquisition of Sinaptic Surgical	750
Proceeds from notes receivable, net of imputed interest		476
Net cash provided by (used in) investing activities	913	(194)
Cash flows from financing activities
Proceeds from issuance of warrant derivative liabilities		3,366
Proceeds from issuance of common stock and prefunded warrants, net of cash fees	4,380	6,075
Proceeds from exercise of warrants, net of cash fees, and deposit for stock issuance (in other current liabilities)	3,624
Proceeds from issuance of common stock in connection with ATM, net of fees	329
Proceeds from issuance of warrants in connection with exercise of warrants	206
Purchase of common stock into treasury	(133)
Proceeds from issuance of common stock in connection with exercise of warrants		2
Principal payment on debt	(206)	(349)
Net cash provided by financing activities	8,200	9,094
Net increase in cash and cash equivalents	542	258
Cash and cash equivalents at beginning of year	3,598	3,340
Cash and cash equivalents at end of year	4,140	3,598
Noncash investing and financing activities
Reduction of derivative liability upon exercise of warrants		1
Deemed dividend related to warrant inducement and issuance of warrants	6,719
Right of use asset for amended lease liability – decrease		307
Debt issued for prepaid insurance	180	335
Agent warrant offering cost allocated to equity		13
Supplemental cash flow information
Cash paid for interest	$ 52	$ 29

Consolidated Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2025	Dec. 31, 2024
Account and other receivables, allowance	$ 2,400	$ 61,000.0
Treasury stock common, shares	50,424
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	3,970,869	1,342,853
Common stock, shares outstanding	3,970,869	1,342,853
Series B Convertible Preferred Stock [Member]
Convertible preferred stock, par value	$ 0.01	$ 0.01
Convertible preferred stock, shares authorized	130,000,000	130,000,000
Convertible preferred stock, shares issued	19	19
Convertible preferred stock, shares outstanding	19	19
Series C Convertible Preferred Stock [Member]
Convertible preferred stock, par value	$ 0.01	$ 0.01
Convertible preferred stock, shares authorized	130,000,000	130,000,000
Convertible preferred stock, shares issued	50	50
Convertible preferred stock, shares outstanding	50	50
Series D Convertible Preferred Stock [Member]
Convertible preferred stock, par value	$ 0.01	$ 0.01
Convertible preferred stock, shares authorized	130,000,000	130,000,000
Convertible preferred stock, shares issued	180	180
Convertible preferred stock, shares outstanding	180	180

Intangible Assets (Tables)

12 Months Ended

Dec. 31, 2025

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Intangible Assets

Intangible assets consisted of the following (in thousands):

Schedule of Intangible Assets

	2025			2024
	As of December 31,
	2025			2024
Trademarks and other patent related intangible assets	$	195		$	50
Less: accumulated amortization		(53	)		(34	)
Intangible assets,net	$	142		$	16

Inventories (Tables)

12 Months Ended

Dec. 31, 2025

Inventory Disclosure [Abstract]

Schedule of Components of Inventory

The components of inventory were as follows (in thousands):

Schedule of Components of Inventory

	2025		2024
	As of December 31,
	2025		2024
Raw materials	$	402	$	629
WIP		296		182
Finished goods		346		156
Inventory net	$	1,044	$	967

Stock-Based Compensation

12 Months Ended

Dec. 31, 2025

Share-Based Payment Arrangement [Abstract]

Stock-Based Compensation

9. Stock-Based Compensation

A summary of the Company’s outstanding stock option activity for the years ended December 31, 2025 and 2024 is as follows:

Schedule of Stock Option Activity

				December 31, 2025
				Weighted- Average Exercise		Weighted- Average Remaining Contractual Life		Intrinsic
	Options			Price		(Years)		Value
As of December 31, 2024		35		$	18,872		5.5		-
Granted		170,000			3.65		9.4		-
Exercised		-			-		-		-
Forfeited		-			-		-		-
Expired		(9	)		17,540		-		-
As of December 31, 2025		170,026		$	6.65		9.4	$	77,600
Exercisable at December 31, 2025		170,026		$	6.65		9.4	$	77,600
Vested and expected to vest at December 31, 2025		170,026		$	6.65		9.4	$	77,600

				December 31, 2024
				Weighted- Average Exercise		Weighted- Average Remaining Contractual Life		Intrinsic
	Options			Price		(Years)		Value
As of December 31, 2023		60		$	21,954		6.9		-
Granted		-			-		-		-
Exercised		-			-		-		-
Forfeited		(24	)		3,861,275		-		-
Expired		(1	)		891,768,343		-		-
As of December 31, 2024		35		$	18,872		5.5	$	-
Exercisable at December 31, 2024		35		$	24,292		6.1	$	-
Vested and expected to vest at December 31, 2024		10		$	38,168		5.5	$	-

The Company estimates the fair value of each stock option on the grant date using the Black-Scholes-Merton valuation model, which requires several estimates including an estimate of the fair value of the underlying common stock on grant date. The expected volatility was based on an average of the historical volatility of the Company. The expected term was contractual life of option. The risk-free interest rate was based on the U.S. Treasury yield curve in effect at the time of grant for the expected term of the option.

Unrecognized stock-based compensation as of December 31, 2025 is as follows (in thousands):

Unrecognized

Stock-Based

Compensation

Weighted

Average

Remaining
of

Recognition
(in years)

Stock options

0.0

Stock grants

1,497

0.9

Property and Equipment (Tables)

12 Months Ended

Dec. 31, 2025

Property, Plant and Equipment [Abstract]

Schedule of Components of Property and Equipment

The following is a summary of the components of property and equipment (in thousands):

	2025			2024
	As of December 31,
	2025			2024
Manufacturing and lab equipment	$	1,783		$	2,220
Leasehold improvements		989			968
Software and computer equipment		674			664
Furniture and equipment		82			118
Property and equipment, gross		3,528			3,970
Less: accumulated depreciation		(3,052	)		(3,048	)
Property and equipment, net	$	476		$	922

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Preferred Stock [Member]	Common Stock [Member]	Treasury Stock, Common [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2023				$ 279,486	$ (270,714)	$ 8,772
Balance, shares at Dec. 31, 2023	256	26,603
Stock based compensation				82		82
Stock based compensation, shares		14
Common stock issued for cash, net of fees		$ 11		5,644		5,655
Common stock issued for cash, net of fees, shares		1,119,357
Warrants issued for warrant inducement				406		406
Extinguishment of derivative liabilities upon exercise of warrants				1		1
Issuance of common stock from the exercise of prefunded warrants for cash		$ 1		1		2
Issuance of common stock from the exercise of prefunded warrants for cash, shares		63,079
Redemption of preferred stock
Redemption of preferred stock, shares	(7)	(1,833)
Redemption of preferred stock, shares	7	1,833
Round up of shares issued in reverse stock split		$ 1		(1)
Round up shares issued in reverse split, shares		131,967
Net loss					(11,024)	(11,024)
Balance of as December 31, 2025 at Dec. 31, 2024		$ 13		285,619	(281,738)	3,894
Balance, shares at Dec. 31, 2024	249	1,342,853
Stock based compensation		$ 3		1,993		1,996
Stock based compensation, shares		330,332
Common stock issued for cash, net of fees		$ 12		4,368		4,380
Common stock issued for cash, net of fees, shares		1,171,189
Warrants issued for warrant inducement				6,719		6,719
Net loss					(10,364)	(10,364)
Issuance of common stock in connection with ATM, net of fees		$ 1		328		329
Issuance of common stock in connection with ATM, net of fees, shares		86,887
Issuance of common stock from the cashless exercise of warrants		$ 2		(2)
Issuance of common stock from the cashless exercise of warrants, shares		148,933
Common stock and warrants issued for cash, net of fees		$ 7		2,138		2,145
Common stock and warrants issued for cash, net of fees, shares		724,649
Issuance of common stock for business acquisition		$ 2		680		682
Issuance of common stock for business acquisition, shares		216,450
Deemed dividend related to warrant inducement				(6,719)		(6,719)
Purchase of common stock into Treasury			(133)			(133)
Balance of as December 31, 2025 at Dec. 31, 2025		$ 40	$ (133)	$ 295,124	$ (292,102)	$ 2,929
Balance, shares at Dec. 31, 2025	249	4,021,293

Leases (Tables)

12 Months Ended

Dec. 31, 2025

Leases

Schedule of Operating Lease Future Minimum Payments

Operating lease future minimum payments together with the present values as of December 31, 2025, are summarized as follows:

Years Ending December 31,	Amount
2026	$	668
2027		688
2028		709
2029		730
2030		752
Thereafter		643
Total future minimum lease payments		4,190
Less amounts representing interests		(948	)
Present value of lease liability		3,242

Current portion of operating lease liability		398
Long-term portion operating lease liability	$	2,844

Schedule of Income Loss Before Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Effective Income Tax Rate Reconciliation [Line Items]
Income before taxes	$ (10,364)	$ (11,024)
Domestic Tax Jurisdiction [Member]
Effective Income Tax Rate Reconciliation [Line Items]
Income before taxes	(10,364)	(11,024)
Foreign Tax Jurisdiction [Member]
Effective Income Tax Rate Reconciliation [Line Items]
Income before taxes

- Definition

Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-4

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-21

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(11))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 14: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

+ Details

401(k) Plan

12 Months Ended

Dec. 31, 2025

Retirement Benefits [Abstract]

401(k) Plan

12. 401(k) Plan

Effective June 1, 2004, the Company adopted a defined contribution retirement plan under Section 401(k) of the Internal Revenue Code. The plan covers substantially all employees. Eligible employees may contribute amounts to the plan, via payroll withholdings, subject to certain limitations. The plan permits, but does not require, additional matching contributions to the plan by the Company on behalf of the participants in the plan. The Company incurred approximately $0.1 million relating to retirement contributions for each of the years ended December 31, 2025 and 2024.